39TH ANNUAL ESDR MEETING - Konferenciakalauz

39TH ANNUAL
ESDR MEETING
9-12 September 2009 Budapest, Hungary
PROGRAM BOOK
1
1
In partnership with:
European Epidermal Barrier Research Network
European Dermato-Epidemiology Network
European Immunodermatology Society
European Society for Pigment Cell Research
European Society of Dermatopathology
Fondation René Touraine
www.esdr.org

Immunoglobulin
as designed by nature
For full prescribing information please refer to the Summary of Product Characteristics:
Intratect® - Human Normal Immunoglobulin for Intravenous Administration, Ph. Eur. Composition: 1ml of solution contains: human plasma protein 50mg, thereof at least 96% is IgG, excipients: Glycine and water for
injection. Indications: Replacement therapy in: Primary immunodefi ciency syndromes such as: - congenital agammaglobulinaemia and hypogammaglobulinaemia, - common variable immunodefi ciency, - severe combined
immunodefi ciency, - Wiskott-Aldrich syndrome; Myeloma or chronic lymphocytic leukaemia with severe secondary hypogammaglobulinaemia and recurrent infections; Children with congenital AIDS and recurrent
infections. Immunomodulation: Idiopathic thrombocytopenia purpura (ITP), in children or adults with a high risk of bleeding or prior to surgery to correct the platelet count; Guillain-Barré syndrome, Kawasaki disease.
Allogeneic bone marrow transplantation. Contraindication: Hypersensitivity to any of the components. Hypersensitivity to homologous immunoglobulins especially in very rare cases of IgA defi ciency when the patient
has antibodies against IgA. Special warnings and special precautions for use: Certain adverse may occur more frequently: in cases of high rate of infusion, in patients with hypo- or agammaglobulinaemia with or without
IgA defi ciency, in patients who receive human normal immunoglobulin for the fi rst time or, in rare cases, when the product is switched or there is a long interval since the previous infusion. Rarely, human normal immunoglobulin
can induce a fall in blood pressure with anaphylactic reaction, even in patients who had previously tolerated treatment with human normal immunoglobulin. Cases of acute renal failure have been reported
in patients receiving IVIg therapy. Standard measures to prevent infections resulting from the use of medicinal products prepared from human blood or plasma include the selection of donors, screening of individual
donations and plasma pools for specifi c markers of infection and the inclusion of effective manufacturing steps for the the inactivation/removal of viruses. Despite this, when medicinal products prepared from human
blood or plasma are administered the possibility of transmitting infective agents cannot be totally excluded. This also applies to unknown or emerging viruses and other pathogens. Undesirable effects: Adverse reactions
such as chills, headache, fever, vomiting, allergic reactions, nausea, arthralgia, low blood pressure and moderate back pain may occur occasionally. Rarely IVIg may cause a sudden fall in blood pressure and, in isolated
cases, anaphylactic shock, even when the patient has shown no hypersensitivity to previous administration. Cases of reversible aseptic meningitis, isolated cases of reversible haemolytic anaemia/haemolysis, rare cases
of transient cutaneous reactions, and increase in serum creatinine level and/or acute renal failure have been observed with IVIg. Very rarely thromboembolic reactions such as myocardial infarction, stroke, pulmonary
embolism, deep vein thrombosis may occur.
Biotest Pharma GmbH · Landsteinerstr. 5 · D-63303 Dreieich, Germany · www.biotest.de

TABLE OF CONTENTS
Table of ConTenTs
Acknowledgment of Sponsors of the 39th Annual ESDR Meeting 2009.............................................. 5
Meeting Organisers................................................................................................................................. 5
Welcome to Budapest............................................................................................................................. 7
Social Program........................................................................................................................................ 8
Scientific Program Highlights
Major lectures................................................................................................................................... 9
Postgraduate Course......................................................................................................................... 9
Clinical saturday................................................................................................................................ 9
esDR Meeting Digest......................................................................................................................... 9
Plenary Sessions..................................................................................................................................... 11
Concurrent Sessions .............................................................................................................................. 14
Day-by-Day Program
Wednesday 9 september.................................................................................................................. . 22
Thursday 10 september. .................................................................................................................... 23
friday 11 september.......................................................................................................................... 24
saturday 12 september...................................................................................................................... 25
Special Workshops
skin Cell Migration and Invasion....................................................................................................... 26
CTCl................................................................................................................................................... 27
Satellite Meetings
PXe..................................................................................................................................................... 28
european Immuno-Dermatology society........................................................................................... 29
european Pigment Cell Research society......................................................................................... 30
european epidermal barrier Research network.............................................................................. 31
neurobiology of the skin.................................................................................................................... 32
european society for Dermatopathology........................................................................................... 33
european Dermato-epidemiology network...................................................................................... 34
Eastern European Session ..................................................................................................................... 35
Sponsored Symposia
biotest, 10 september.......................................................................................................................... 36
Galderma, 11 september..................................................................................................................... 37
General Information................................................................................................................................ 38
Exhibitor Information
list of exhibitors and map................................................................................................................ 40
Poster Information/Slide Preview Room............................................................................................... 41
About the ESDR
Current officers of the esDR board.................................................................................................. 42
Past officers of the esDR board....................................................................................................... 42
esDR Committees.............................................................................................................................. 43
Patron Members of the esDR........................................................................................................... 43
abstract Reviewers in 2009............................................................................................................... 43
list of esDR awards and Honourary Memberships......................................................................... 44
future esDR Meetings....................................................................................................................... 44
TABLE OF CONTENTS

PLATINUM SPONSOR OF THE 2009 ESDR MEETING
GOLD SPONSOR OF THE 2009 ESDR MEETING
SPONSORS OF THE 2009 ESDR MEETING
astellas
Ce.R.I.e.s
Chanel R&T
Hungarian Dermatological society
Janssen-Cilag
lVMH Recherche
ESDR SCIENTIFIC PROGRAM COMMITTEE
eugene Healy, southampton (Chair)
antonio Costanzo, Rome
Reinhard Dummer, Zurich
alexander enk, Heidelberg
alain Mauviel, Paris
Vincent Piguet, Geneva
ESDR OFFICE
european society for Dermatological Research
7 Rue Cingria
CH-1205 Geneva
switzerland
Tel: +41 22 321 48 90
fax: +41 22 321 48 92
email: office@esdr.org
Web: www.esdr.org
CME CREDITS
nékám foundation
sanofi Pasteur MsD aG
LOCAL ORGANISING COMMITTEE
executive Committe
sarolta Kárpáti, budapest (Chair)
lajos Kemény, szeged
Éva Remenyik, Debrecen
Committe Members
Zsuzsanna bata-Csörgo, szeged
Zita batthyányi, Pécs
antal blazsek, budapest
Márta Medvecz, budapest
Rolland Gyulai, szeged
István Juhász, Debrecen
Klaudia Preisz, budapest
andrea szegedi, Debrecen
Márta széll, szeged
norbert Wikonkál, budapest (secretary)
MEETING SECRETARIAT (PCO)
MoTesZ Congress and Travel agency
nádor u. 36
H-1051 budapest
Hungary
Tel: +36 1 311 66 87
fax: +36 1 383 79 18
email: esdrbudapest2009@motesz.hu
Web: www.motesz.hu
The "39th annual esDR Meeting" is designated for a maximum of (or "for up to") 18 hours of european
external CMe credits. each medical specialist should claim only those hours of credit that he/she actually
spent in the educational activity. CMe certificates are available upon request at the registration desk.
SPONSORS
ORGANISATION

Don’t let zoster hold them back
A VACCINE WILL SOON BE AVAILABLE.
1. Bowsher D. The lifetime occurrence of Herpes zoster and prevalence of post-herpetic neuralgia: A retrospective survey in an 6 elderly population. Eur J Pain 1999; 3: 335–42. 2. Miller E, Marshall R,
Vudien J. Epidemiology, outcome and control of varicella-zoster infection. Rev Med Microbiol 1993; 4: 222–30.
6

Welcome to ESDR 2009
It is our utmost pleasure to welcome you to the 39th annual
Meeting of the esDR and to budapest, a city often called the
Queen of the Danube. The meeting organisers selected the
dynamically developing semmelweis University as main
venue for this event, a place where stephen Rothman,
founder of the investigative dermatology, studied.
Committed to achieving the highest quality of
dermatological science, the program of the budapest
2009 esDR Meeting will feature over 600 posters from
36 countries, plenary lectures, concurrent sessions,
symposia and workshops on hot topics of research, putting
forward the most recent developments in experimental
dermatology.
During the time of the conference the 14-acre orczy
Garden park will be at our sole disposal just across the
street from the meeting venue, with its lush walkways,
ponds, benches, sport facilities and a running track.
The Run for atopic Dermatitis, an early friday morning
4km running race will be organised for those of you
who wish to stay fit and balanced during the time of the
conference.
stephen Rothman's former piano will be exhibited at the
meeting venue and every participant is free to follow in his
musical footsteps.
Welcome from the ESDR President
The first esDR meeting in the former eastern europe, the
other side of the iron curtain.
Just two decades ago, it was almost impossible to organise
a meeting gathering dermatologists and cutaneous
biologists from western and eastern countries.
This meeting marks the beginning of a new chapter in
the time of these new democracies and their ambitious
and intelligent people who will engage more and more in
research.
Today, budapest is a bridge between east and West. We
hope to use it to build up new connections and encourage
many young researchers in the field of dermatology to join
our active society.
still, there are huge problems and limitations for our
colleagues in eastern europe. Unfortunately, the economic
crisis is worsening the plight of many academic institutions.
However, we should never forget that human intelligence
and enthusiasm are the most precious gifts and,
fortunately, our colleagues maintain these traits despite
discouraging circumstances.
one of the most important roles of the esDR is to promote
the presentation of new research data and ideas at our
annual scientific meeting and clinically oriented symposia.
7
The open-air Hungarian Gala evening will take place on
friday at the bárka Theatre hidden behind the walls of
the orczy Garden. at this event you will vote to decide
which University Department has the best cooking skills
in Hungary: Debrecen, Pécs, szeged or budapest. Thanks
to the participation of the Gerbaud Kitchen’s chefs, you
can give Hungarian food a real try in the marquee during
the dinner. Hungarian dance classes will be available in
the bárka Theatre, and you can apply your newly acquired
dance knowledge in the subsequent disco or stay in the
marquee for live music and dancing.
budapest has always been famous for its hospitality,
and the organisers will do their best during the meeting
to advance this reputation and provide a comforting
background for a rewarding meeting and a wonderful stay.
Prof Sarolta Kárpáti
Chair, local organising Committee
esDR board Member
This year's meeting, thanks to the outstanding effort of
the scientific Program Committee, offers an exciting and
stimulating program with over 200 oral presentations and
over 600 posters. I encourage you to attend some of the
many excellent symposia and satellite meeting sessions on
offer. Your active participation is essential to the success
of the meeting, so please do not hesitate to ask questions,
make comments, and enjoy the hospitality offered by the
budapest organisers in the evening!
on behalf of the esDR I would personally like to thank all
who have and will contribute to the success of this meeting,
including our international guests, partner societies,
sponsors and members and especially Prof sarolta Kárpáti
and her team for all the engagement organising this year's
meeting in beautiful budapest.
Prof Reinhard Dummer
President, european society for Dermatological Research
WELCOME

SOCIAL
PROGRAM
OUTDOOR
ACTIVITIES
ESDR WELCOME RECEPTION
Thursday 10 September 2009, 19.00-22.00
all delegates are invited to attend the esDR Welcome Reception at the semmelweis University on Thursday 10
september 2009. The reception will also be a first opportunity to view posters, with food and beverage stations
nearby.
ESDR 2009 HUNGARIAN GALA EVENING
Friday 11 September 2009, 19.30-24.00
Orczy Garden, Bárka Theatre Entrance (Ülloi utca 82)
The 2009 esDR Gala evening will be held under a large tent in the orczy Garden and will have a strong Hungarian
flavour, with music, dancing and traditional food and wine. We will also have use of the bárka Theatre a short
walk away from the tent. The bárka will host Hungarian dance lessions and a DJ for those who would prefer club
sounds to live music.
all participants are invited to attend this relaxed and convivial event without an additional charge. Please wear
comfortable and informal clothing for the evening. Hosts and hostesses will be on hand to guide you to the bárka
Theatre entrance to the garden.
Program (Tent)
19.30 arrival at bárka Theatre entrance to garden
19.30-20.20 Hungarian Cooking Competition and aperitif
20.20-21.20 Dinner buffet
21.20-21.30 Presentation of prizes and short speeches
21.30-24.00 live music and dancing
Program (Bárka Theatre)
21.30-22.00 Hungarian folk Dancing lessons (studio)
21.30-24.00 DJ - new Jazz-funk & bossanova (Main Theatre)
Practical Info
Transport
at the end of the evening, taxis will be available to transport you back to hotels. for those wishing to travel by
metro, the last train leaves the first stop on line 3 at 23.15. Please ask the registration desk for more information.
Toilets
located in the bárka Theatre.
Wet Weather
In case of bad weather, the party will continue but consider bringing an umbrella for the walk from the metro
station to the entrance.
ORCZY GARDEN - A GREEN SPACE FOR ESDR 2009
Orczy Garden
located opposite the esDR 2009 meeting venue, orczy Garden is a 14-hectare park comprising grassed areas,
promenades, sports fields and a lake. The garden has been exclusively reserved for esDR 2009 participants as a
leisure space. security guards will be monitoring the entrances and exits, so please take your meeting badge with
you to access the garden.
opening Hours
Thursday 10 september - 07.00-17.00
friday 11 september - 06.00-24.00
saturday 12 september - 07.00-15.00
FUN RUN FOR ATOPIC DERMATITIS
Date: friday 11 september 2009
location: orczy Garden running track (opposite esDR 2009 meeting venue)
Time: 07.00 (meet at running track at 06.45)
Distance: 4km
The esDR and local organising Committee have organised a fun run for atopic dermatitis on the 400m running
track opposite the esDR 2009 meeting venue. The run is open to 50 participants so please register early for
this event when you arrive in budapest. several prizes will be awarded at the Gala evening on friday and all
participants will receive a T-shirt. Changing rooms available by running track.
This event is kindly supported by astellas.
8

SCIENTIFIC AND EDUCATIONAL HIGHLIGHTS
MAJOR LECTURES
■ ESDR Guest Lecture: Cancer
Moshe Oren (Israel)
p53 and Cancer: a Complex Relationship
■ Merck Serono Lecture
Ronald N. Germain (USA)
The Role of Cell Dynamics in Immune system
function: Insights from High-resolution Intravital
Imaging of lymphoid and Peripheral Tissue sites
supported by
■ Rudi Cormane Lecture
Lars French (Switzerland)
The Inflammasome, Danger sensing and skin Disease
■ René Touraine Lecture
Sabine Werner (Switzerland)
stromal-epithelial Interactions in Wound Repair
and Cancer
POSTGRADUATE COURSE
our knowledge in basic science is rapidly increasing.
Dermatology has numerous interfaces with basic
science fields. Thus, a constant update in these areas is
crucial for the further development of dermatological
research. The purpose of the Postgraduate Course is
to provide overviews about primarily non-dermatologic
topics that are relevant for experimental and clinical
dermatology. These talks are principally intended as
essential updates for “non-experts”.
Program
10 september 2009, 11.00-12.30
Chairs: Tilo biedermann, Robert Gniadecki
■ Eva Mezey (Bethesda)
stem Cells: bumpy Road from bench to bedside
■ Carien Niessen (Cologne)
Intercellular adhesion and Polarity in skin
Morphogenesis and Pathogenesis
■ Miklós Palkovits (Budapest)
bilateral Connections between the autonomic
nervous system and the structures of the
epidermis
ESDR MEETING DIGEST
Saturday 12 September 2009, 14.15-15.15
Speakers: John McGrath, Martin Röcken, Thomas Schwarz
9
CLINICAL SATURDAY
The main mission of the esDR is to foster basic
research in dermatology and skin biology. To increase
the exchange between basic scientists and clinicians
at the annual meeting, the esDR has included a
“Clinical saturday” as part of the regular program.
by offering Clinical saturday and industry sponsored
symposia, the esDR hopes to make the meeting as
attractive for clinicians as it always has been for basic
scientists. The esDR feels committed to satisfying the
needs and interests of both scientists and clinicians.
The dialogue and cross fertilization between these
two groups is essential for the future prosperous
development of dermatology.
Clinical saturday 2009 is held in association with the
european academy for Dermatology and Venereology
Program
Clinical saturday I: 12 september 2009, 08.45-10.15
Chairs: Carlo Pincelli, Peter steijlen
■ Pascal Joly (Rouen)
novel Cinical and Therapeutic advances in
autoimmune bullous Diseases
■ Christos Zouboulis (Dessau)
Inflammatory Diseases of sebaceous Glands
■ Sarolta Kárpáti (Budapest)
skin barrier Damage due to enzyme Dysfunctions
Clinical saturday II: 12 september 2009, 11.15-12.45
Chairs: sarolta Kárpáti, erwin Tschachler
■ Stefan Beissert (Münster)
The Role of Regulatory T cells in
Photocarcinogenesis
■ Giovanna Zambruno (Rome)
Update on Inherited epithelial adhesion
Disorders
■ Mona Ståhle (Stockholm)
Genetic susceptibility in Psoriasis
The esDR Meeting Digest is a one-hour summary and analysis of scientific highlights of the 2009 meeting as
seen by three senior scientists. each speaker will focus on a different topic area, extracting important results
from abstracts submittted to the meeting and placing them into a wider context.
SCIENTIFIC
HIGHLIGHTS
ESDR
DIGEST

PLENARY SESSION I: THURSDAY 10 SEPTEMBER 2009, 14.00-16.00
SEMMELWEIS ROOM
Chairs: Hiroshi Shimizu, Georg Stingl
Talk duration is 12 minutes plus 3 minutes questions
Oral 001 [Poster 218]
A dynamic subpopulation of slow-proliferating JARID1B-positive cells is required for long-term
self-renewal of melanoma but not for initial tumor formation
Roesch a 1 , fukunaga-Kalabis M 2 , schmidt b 2 , Zabierowski s 2 , Vogt T 1 , Herlyn M 2 1 Regensburg Univ
Medical Center, Germany 2 The Wistar Institute, Philadelphia, Usa
Oral 002 [Poster 262]
Both hematopoietic and mesenchymal stem cells contribute to the production of basement
membrane protein in bone marrow transplantation treatment model mouse
fujita Y 1 , abe R 1 , Inokuma D 1 , nishie W 1 , nakamura H 1 , akiyama M 1 , sawamura D 2 , shimizu H 1
1 Hokkaido University Graduate school of Medicine, sapporo, Japan 2 Hirosaki University Graduate
school of Medicine, Hirosaki, Japan
Oral 003 [Poster 598]
An amplifying circuit of the innate immune sensing of Staphylococcus aureus: Monomeric
peptidoglycan functions as NOD2 ligand and aggravates TLR mediated inflammation
Volz T 1 , nega M 2 , buschmann J 2 , Kaesler s 1 , Guenova e 1 , Röcken M 1 , Götz f 2 , biedermann T 1
1 Department of Dermatology, University Hospital Tübingen, Germany 2 Department of Microbial
Genetics, eberhard Karls University, Tübingen, Germany
Oral 004 [Poster 458]
Fetal cells persist in maternal chronic wounds, form blood vessels and enhance healing
nassar D, Droitcourt C, Parant o, Mathieu-d’argent e, oster M, Uzan s, Khosrotehrani K, aractingi s
UPMC Univ Paris 6, InseRM UMRs 938, centre de recherche saint antoine, fetal stem cells unit, Paris,
france
Oral 005 [Poster 599]
HIV-1 induces cdc42-dependent filopodia formation to facilitate dendritic cell-t cell trans-infection
nikolic Ds, lehmann M, Garcia e, blanchet fP, Piguet V Department of Dermatology and
Venereology, University Hospitals, Geneva, switzerland
Oral 006 [Poster 186]
A mutation in the histidase gene sensitizes mice to UVB-induced DNA damage: evidence for the
photoprotective role of endogenously produced urocanic acid
barresi C 1 , stremnitzer C 1 , Mlitz V 1 , Kezic s 2 , Ghannadan M 1 , buchberger M 1 , Mildner M 1 , selden
C 3 , Tschachler e 1 , eckhart l 1 1 Medical University of Vienna, Vienna, austria 2 Coronel Institute,
amsterdam, netherlands 3 UCl Medical school, london, UK
Oral 007 [Poster 469]
HIF-1alpha knockdown keratinocytes cannot reconstruct a viable epidermis
ali n 1 , Rezvani H 1 , Varon C 2 , Pain C 1 , Taieb a 1 , De Verneuil H 1 , Mazurier f 1 1 Inserm U876 - Univ.
bordeaux2 , france 2 CnRs UMR5164- Univ. bordeaux2, france
Oral 008 [Poster 263]
Heterogenetic parabiosis and skin grafting murine models (Abcc6-/-) support the metabolic nature
of pseudoxanthoma elasticum
Uitto J, Jiang Q Jefferson Medical College, Philadelphia, Usa
11
PLENARY
SESSIONS

PLENARY
SESSIONS
PLENARY SESSION II: FRIDAY 11 SEPTEMBER 2009, 08.30-11.00
SEMMELWEIS ROOM
Chairs: Martine Bagot, Jouni Uitto
Talk duration is 12 minutes plus 3 minutes questions
Oral 009 [Poster 001]
Generation of myeloid derived suppressor cells during the progression of murine RET melanoma
fujimura T 1 , Mahnke K 1 , Ring s 1 , Umansky V 2 , aiba s 3 , enk aH 1 1 University of Heidelberg, Heidelberg,
Germany 2 German Cancer Research Center, Heidelberg, Germany 3 Tohoku University, Graduate school of
Medicine, sendai, Japan
Oral 010 [Poster 499]
Identification of a novel microRNA regulator of keratinocyte migration and proliferation in wound healing
bertero T 1 , bourget-Ponzio I 1 , loubat a 1 , Techer n 1 , Mari b 2 , barbry P 2 , Meneguzzi G 1 , Ponzio G 1 , Rezzonico R 1
1 InseRM U634, nice, france 2 CnRs UMR 6097, sophia-antipolis, france
Oral 011 [Poster 470]
Cytoskeletal protein Flightless I affects cellular adhesion and blister formation in epidermolysis bullosa
Kopecki Z 1 , arkell R 2 , ludwig R 3 , Zillikens D 3 , Murrell D 4 , Cowin aJ 1 1 Women’s & Children’s Health Research
Inst, north adelaide, australia 2 Molecular Genetics & evolution Group australian nat Univ, aCT, australia 3 Dept
of Dermatology Univ of lubeck, Germany 4 Dept of Dermatology st. George Hospital, sydney, australia
Oral 012 [Poster 002]
Vaccination against autoimmune disease through in vivo silencing of dendritic cells with a specific IL-12/
IL23p40 si-RNA
brück J 1 , Weigert C 1 , Pascolo C 2 , Glocova I 1 , fuchs K 1 , Ghashghaeinia M 1 , Hötzenecker W 1 , Ghoreschi K 1 ,
Röcken M 1 1 Department of Dermatology, Tübingen, Germany 2 University Hospital of Zürich, oncology, Zürich,
switzerland
Oral 013 [Poster 521]
Autoantibody-induced intestinal inflammation and weight loss in experimental epidermolysis bullosa
acquisita
Ishii n 1 , Recke a 2 , Mihai s 2 , Hirose M 2 , Hashimoto T 1 , Zillikens D 2 , ludwig RJ 2 1 Kurume Univ school of
Medicine, Kurume, Japan 2 University of lübeck, Germany
Oral 014 [Poster 003]
Essential roles of actin cytoskeleton formation through mDia1 in skin dendritic cell functions
Hideaki T, Gyohei e, shuh n, Yoshiki M, Kenji K Kyoto University, Kyoto, Japan
Oral 015 [Poster 471]
Cadherin mediated regulation of the tight junctional skin barrier function
Michels C, buchta T, niessen C University of Cologne, Cologne, Germany
Oral 016 [Poster 393]
Differentiation of epidermal keratinocytes from mouse induced pluripotent stem cells
nakamura M, Tokura Y University of occupational and environmental Health, Kitakyushu, Japan
Oral 017 [Poster 331]
Activated Langerhans cells capture external antigens by sending their dendrites out through epidermal tight
junctions
Kubo a 1 , nagao K 1 , Yokouchi M 1 , sasaki H 2 , amagai M 1 1 school of Medicine, Keio University, Tokyo, Japan 2 The
Jikei University school of Medicine, Tokyo, Japan
Oral 018 [Poster 420]
IL-21-activated STAT3 upregulates microRNA-21 expression in CD4+ T cells: pathologically involved in
cutaneous T cell lymphoma?
van der fits l, van Kester Ms, out JJ, smit f, Willemze R, Tensen CP, Vermeer MH lUMC, leiden, netherlands
12

PLENARY SESSION III: FRIDAY 11 SEPTEMBER 2009, 17.00-18.30
SEMMELWEIS ROOM
Chairs: Ervin Epstein, Jean-Hilaire Saurat
Talk duration is 12 minutes plus 3 minutes questions
Oral 019 [Poster 522]
IL-21, a new player in pathogenesis of psoriasis
botti e 1 , Caruso R 2 , sarra M 2 , Diluvio l 1 , Pallone f 2 , Chimenti s 1 , Monteleone G 2 , Costanzo a 1 1 University of
Rome Tor Vergata Dermatology, Rome, Italy 2 University of Rome Tor Vergata Gastroenterology, Rome, Italy
Oral 020 [Poster 174]
Betapapillomavirus infection and cutaneous squamous-cell carcinoma
bouwes bavinck J 1 , neale R 2 , abeni D 3 , de Koning M 4 , Pawlita M 5 , Pfister H 6 , naldi l 7 , Harwood C 8 , Green
a 2 , feltkamp M 1 1 leiden Univ Medical Center, leiden, netherlands 2 Queensland Inst of Medical Research,
brisbane, australia 3 Istituto Dermopatico dell’Immacolata, IDI-IRCCs, Rome, Italy 4 DDl Diagnostic lab, Voorburg,
netherlands 5 German Cancer Research Center (DKfZ), Heidelberg, Germany 6 Inst of Virology, Univ of Cologne,
Germany 7 Dept of Dermatology & GIseD study Center, bergamo, Italy 8 Queen Mary Univ of london, UK
Oral 021 [Poster 264]
Filaggrin-deficient mice have an inherent skin barrier defect and recapitulate key features of atopic eczema
fallon PG 1 , Irvine aD 1 , sasaki T 2 , sandilands a 3 , saunders sP 1 , Presland Rb 4 , fleckman P 4 , Kudoh J 2 ,
amagai M 2 , Mclean I 3 1 Trinity College Dublin, Dublin, Ireland 2 Keio University, Tokyo, Japan 3 University of
Dundee, Dundee, United Kingdom 4 University of Washington, seattle, Usa
Oral 022 [Poster 265]
Long term genetic correction of cancer prone xeroderma pigmentosum skin ex vivo and in vivo
Magnaldo T 1 , Warrick e 2 , Garcia M 3 , bergoglio V 4 , larcher f 3 , Del Rio M 3 , bernerd f 5 1 CnRs, fRe 3086,
faculté de Médecine, nice, france 2 CnRs, fRe 3086, faculté de Médecine, l’oréal france, nice, france
3 CIeMaT-CIbeR de enfermedades Raras, Madrid, spain 4 CnRs, fRe 3086, faculté de Médecine, nice, spain
5 l’oreal advanced Research, Clichy, france
Oral 023 [Poster 394]
Regeneration of hair and epidermis by the receptor activator of NF-kappaB
Mueller C 1 , Duheron V 2 , Hess e 2 , amoasii l2, Paus R 3 1 University of strasbourg, CnRs, strasbourg, france
2 University of strasbourg, strasbourg, france 3 University of lübeck, lübeck, Germany
Oral 024 [Poster 187]
Langerhans cells are required for UV-induced immunosuppression
schwarz a 1 , noordegraaf M 2 , Clausen b 2 , schwarz T 1 1 University Kiel, Kiel, Germany 2 University Rotterdam,
Rotterdam, netherlands
13
PLENARY
SESSIONS

CONCURRENT
SESSIONS
CONCURRENT SESSION I: Immunology
Thursday 10 September 2009, 17.00-18.30
SEMMELWEIS ROOM
Chairs: Alexander Enk, Peter Friedmann
Talk duration is 8 minutes plus 2 minutes questions.
Oral 025 [Poster 004]
Adenosine produced by CD4+CD25+ regulatory T cells suppresses contact hypersensitivity reactions by
engaging the A1 adenosine receptor on vascular endothelium
Ring s 1 , oliver s 2 , Cronstein b 2 , enk aH 1 , Mahnke K 1 1 University Hospital Heidelberg, Heidelberg, Germany
2 new York University school of Medicine, new York, Usa
Oral 026 [Poster 005]
The RhoA effector mDia1 regulate motility and function in T lymphocytes
egawa G 1 , Tanizaki H 1 , okada T 2 , narumiya s 1 , Miyacchi Y 1 , Kabashima K 1 1 Kyoto University, Kyoto, Japan
2 RIKen, Yokohama, Japan
Oral 027 [Poster 006]
Local UVB-induced immunosuppression is mediated by IL-10-produing and OX40L-positive mature
Langerhans cells
Yoshiki R 1 , Kabashima K 2 , sugita K 1 , nakamura M 1 , Tokura Y 1 1 University of occupational and environmental
Health, Kitakyushu, Japan 2 Kyoto University, Kyoto, Japan
Oral 028 [Poster 007]
The role of mast cells in contact hypersensitivity using newly-generated mast cell-specific conditional
depletion model
otsuka a, Miyachi Y, Kabashima K Kyoto University, Kyoto, Japan
Oral 029 [Poster 008]
Surgical denervation of skin in the KC-Tie2 mouse model of psoriasis eliminates dendritic cell infiltrate,
decreases IL-23 protein expression and improves acanthosis
ostrowski sM, belkadi aM, Matheny C, Diaconu D, Wolfram Ja, Hatala Da, Ward nl Case Western Reserve
University, Cleveland, Usa
Oral 030 [Poster 009]
Alteration of the migratory behavior of UV-induced regulatory T cells in vivo
schwarz a, schuller W, schwarz T University of Kiel, Kiel, Germany
Oral 031 [Poster 010]
IL-4 therapy of psoriasis selectively abrogates IL-23 and TH17 immune responses in humans
Guenova e 1 , Ghoreschi K 1 , Hötzenecker W 1 , sauer K 1 , Weindl G 2 , Tham M 1 , schäkel K 3 , schaller M 1 , Röcken M 1 ,
biedermann T 1 1 eberhard Karls University Tübingen, Germany 2 freie Universität berlin, Germany 3 Technische
Universität Dresden, Germany
Oral 032 [Poster 011]
Th22 cells represent a distinct human T lymphocyte subset of tissue-signaling leukocytes
eyerich K 1 , foerster s 2 , Pennino D 3 , Carbone T 3 , Cianferani f 4 , odorisio T 4 , Traidl-Hoffmann C 1 , Durham s 5 ,
schmidt-Weber C 2 , Cavani a 3 1 ZaUM – Center for allergy & environment, Div of environmental Dermatology
& allergy HHZ/TUM, Munich, Germany 2 Molecular Immunology, Dept of allergy & Clinical Immunology, nHlI,
Imperial College, london, UK 3 lab of Immunology, Istituto Dermopatico dell’Immacolata, IRCCs, Rome,
Italy 4 lab of Cellular & Molecular biology, Istituto Dermopatico dell’Immacolata, IRCCs, Rome, Italy 5 Upper
Respiratory Medicine, Dept of allergy & Clinical Immunology, nHlI, Imperial College, london, UK
Oral 033 [Poster 012]
The functional spectrum of cytotoxic DCs: different roles of IFNα and MHC I in pDCs and mDCs
Kalb M, stary G, Koszik f, stingl G Department of Dermatology, DIaID, Medical University of Vienna, Vienna,
austria
14

CONCURRENT SESSION II: Clinical Investigation and Epidemiology
Thursday 10 September 2009, 17.00-18.30
KAPOSI ROOM
Chairs: Jan Nico Bouwes Bavinck, Nick Reynolds
Talk duration is 8 minutes plus 2 minutes questions.
Oral 034 [Poster 090]
The effects of filaggrin mutations on barrier function in eczema patients
abdul Ghaffar s 1 , Tan sP 1 , Campbell le 2 , lee lH 1 , sergeant a 1 , Mclean WI 1 , Weller R 1 1 The University of
edinburgh, UK 2 University of Dundee, UK
Oral 035 [Poster 091]
Are the superantigens producing Staphylococcus aureus strains more resistant to antimicrobial peptides?
baranska-Rybak W 1 , szultka l 1 , sokolowska-Wojdylo M 1 , naumiuk l 2 , nowicki R 1 , Kamysz W 1 , Roszkiewicz J 1
1 Med Univ, Gdansk, Poland 2 lipopharm, Zblewo, Poland
Oral 036 [Poster 092]
The use of Sulfasalazine and Pentoxiphylline as an adjuvant therapy for the treatment of Pemphigus Vulgaris:
A comparative study
el Darouti M, Marzouk s, abdel Hay R, el Tawdy a, fawzy M, leheta T, Gammaz H, al Gendy n faculty of
Medicine, Cairo University, Cairo, egypt
Oral 037 [Poster 093]
Switching azathioprine to mycophenolate reduces UVA photosensitivity in renal transplant recipients
Hofbauer G 1 , straub G 1 , Meyer R 1 , Karran P 2 , attard n 2 , french l 3 , Wüthrich R 3 , serra a 3 1 Univ Hosp Zurich,
Dept of Derm, switzerland 2 Cancer Res UK london Res Inst, Clare Hall labs, Herts, UK 3 Univ Hosp Zurich, Div
of nephrology, switzerland
Oral 038 [Poster 094]
Expression of epidermal differentiation and antimicrobial proteins after treatment with pimecrolimus versus
betamethasone in atopic dermatitis
Jensen J 1 , scherer a 2 , bräutigam M 2 , Gläser R 1 , Witt M 1 , fölster-Holst R 1 , Proksch e 1 1 University of Kiel,
Kiel, Germany 2 novartis Pharma, basel, switzerland
Oral 039 [Poster 095]
A risk-benefit assessment of Adalimumab, Etanercept, and Infliximab in psoriasis
strober b 1 , langley R 2 , Rozzo s 3 1 new York University school of Medicine, new York, new York, Usa
2 Dalhousie University, Halifax, nova scotia, Canada 3 abbott laboratories, abbott Park, Illinois, Usa
Oral 040 [Poster 166]
Investigation of cell therapy for generalized severe recessive dystrophic epidermolysis bullosa by
intradermal allogeneic fibroblasts randomized against placebo injections
Yan Wf 1 , Venugopal s 1 , frew JW 1 , Tran K 2 , sturm M 3 , fogarty J 3 , Marinkovich P 4 , Igawa s 5 , Ishida-Yamamoto a 5 ,
Murrell Df 1 1 st George Hospital, Univ of nsW, australia 2 seals, st George Hosp, Univ of nsW, sydney, australia
3 Cell and Tissue Therapies Wa, Royal Perth Hosp, Perth, australia 4 stanford Univ, stanford, Usa 5 asahikawa
Medical College, Japan Chairs: Jan nico bouwes bavinck, nick Reynolds
Oral 041 [Poster 175]
Temporal patterns of disease in eczema: the failure of objective and subjective measures of disease activity
to match
Murray Cs, Rees Jl The University of edinburgh, edinburgh, United Kingdom
Oral 042 [Poster 176]
Psoriasis is not associated with an increased risk of cardiovascular hospitalizations: results of a large
population based Dutch cohort
Wakkee M, Herings R, nijsten T erasmus Medical Center, Rotterdam, netherlands
15
CONCURRENT
SESSIONS

CONCURRENT
SESSIONS
CONCURRENT SESSION III: Photobiology, Pigmentation and Melanoma
Thursday 10 September 2009, 17.00-18.30
GRUBY ROOM
Chairs: Eugene Healy, Mauro Picardo
Talk duration is 8 minutes plus 2 minutes questions.
Oral 043 [Poster 219]
Micro-array analysis reveals that melanocortin 1 receptor is down-regulated by SLC24A5 knock-down in
normal human melanocytes
Wilson s, askew se, lim fl, Gunn Da, Ginger Rs, Green MR Unilever R&D, bedford, United Kingdom
Oral 044 [Poster 188]
In vivo antagonism of the aryl hydrocarbon receptor prevents UV-induced immunosuppression
schuller W, schwarz T, schwarz a University Clinics schleswig-Holstein, Campus Kiel, Kiel, Germany
Oral 045 [Poster 189]
The pro-apoptotic role of RAIDD in vitro and in vivo
schuepbach-Mallepell s 1 , Roques s 1 , logette e 2 , Tschopp J 2 , Gaide o 1 1 Geneva University Hospital,
switzerland 2 University of lausanne, switzerland
Oral 046 [Poster 220]
c-Kit Mutants Require Hypoxia-Inducible Factor 1α to Transform Melanocytes
Monsel G 1 , ortonne n 2 , bagot M 2 , bensussan a 1 , Dumaz n 1 1 InseRM U976, Paris, france 2 Hôpital Henri
Mondor, Créteil, france
Oral 047 [Poster 190]
Treg/Th17 axis in 8-methoxypsoralen plus ultraviolet-A response of a psoriasis-like skin disorder in mice
singh TP 1 , schön MP 2 , Michaelis K 3 , Wang XJ 4 , Wolf P 1 1 Dept of Derm, Med Univ of Graz, austria 2 Dept of
Derm, Univ Med Ctr Göttingen, Germany 3 Univ of Würzburg, Germany 4 Dept of Path, Head & neck Cancer Res,
Univ of Colorado Denver, Usa
Oral 048 [Poster 221]
AP-1 inhibition identifies cooperation of INK4 and Cip/Kip signaling pathways to suppress human melanoma
Jalili a 1 , Wagner C 1 , Mertz KD 1 , Pashenkov M 1 , lupien M 2 , brunet JP 3 , Ramaswamy s 4 , Golub TR 3 , stingl
G 1 , Wagner sn 1 1 DIaID, Dept of Dermatology, Medical Univ of Vienna, austria 2 norris Cotton Cancer Center,
Dartmouth-Hitchcock Med Center, lebanon, Usa 3 The broad Inst of MIT & Harvard, Cambridge, Usa
4 Massachusetts General Hosp Center for Cancer Research & Dept of Medicine, Charlestown, Usa
Oral 049 [Poster 222]
Ebselen induces peripheral actin depolymerisation and inhibits melanosomal transfer through a melanocytedependent
mechanism
Kasraee b, nikolic D, salomon D, Piguet V, fontao l, sorg o, saurat JH Geneva University Hospital, switzerland
Oral 050 [Poster 223]
GLI2, A TGF-beta-Inducible Target, Promotes Melanoma Invasion and Metastasis
alexaki VI, Javelaud D, Dennler s, Verrecchia f, Mauviel a InseRM U697, Paris, france
Oral 051 [Poster 224]
Functional melanocortin 1 receptors are located in the melanosome of pigment cells
Jackson Cl 1 , singh s 2 , Robinson sJ 1 , Kumar P 1 , Page aM 1 , friedmann Ps 1 , Tobin DJ 2 , Healy e 1 1 University of
southampton, UK 2 University of bradford, UK
16

CONCURRENT SESSION IV: Genetic Disease, Gene Expression and Gene Therapy
Thursday 10 September 2009, 17.00-18.30
NEKAM ROOM
Chairs: John McGrath, Takashi Hashimoto
Talk duration is 8 minutes plus 2 minutes questions.
Oral 052 [Poster 266]
In vitro correction of COL7A1 gene mutations using RNA trans-splicing
Murauer eM 1 , Gache Y 2 , Gratz IK 1 , Klausegger a 1 , Muss W 3 , Gruber C 1 , Meneguzzi G 2 , Hintner H 4 , bauer JW 1
1 laboratory for Molecular Therapy, eb-house austria, Univ Hospital salzburg, austria 2 InseRM U634, faculty
of Medicine, Univ of nice-sophia antipolis, nice, france 3 Institute of Pathology, Univ Hospital salzburg, austria
4 eb-house austria, Department of Dermatology, Univ Hospital salzburg, austria
Oral 053 [Poster 267]
Plectin expression in epidermolysis bullosa simplex (EBS) with muscular dystrophy vs. in EBS with pyloric
atresia
natsuga K 1 , nishie W 1 , akiyama M 1 , ouchi T 3 , Ishiko a 3 , Hirako Y 4 , owaribe K 4 , bruckner-Tuderman l 2 ,
shimizu H 1 1 Hokkaido Univ Graduate school of Medicine, sapporo, Japan 2 Univ Medical Center freiburg,
Germany 3 Keio Univ school of Medicine, Tokyo, Japan 4 nagoya Univ Graduate school of science, Japan
Oral 054 [Poster 268]
Hereditary Painful Callosities, a form of Palmar-Plantar Keratoderma, is caused by dominant negative
mutations in the 2B helix of keratin K6c
easter Te, Ruge f, bowden Pe Cardiff University, Cardiff, United Kingdom
Oral 055 [Poster 269]
Plectin mutations underlie epidermolysis bullosa simplex in patients with wild type KRT5 and KRT14 alleles
bolling MC 1 , Jongbloed JD 1 , smith fJ 2 , Mclean WH 2 , Jonkman Mf 1 1 University Medical Center Groningen,
netherlands 2 University of Dundee, UK
Oral 056 [Poster 270]
Functional restoration of inherited epidermolysis bullosa by bone marrow-derived adult stem cells
Ghoreschi K 1 , Huenefeld C 1 , Glocova I 1 , Mueller-Hermelink e 1 , fehrenbacher b 1 , biedermann T 1 , amagai M 2 ,
Manz MG 3 , schaller M 1 , Röcken M 1 1 eberhard Karls University, Tübingen, Germany 2 Keio University school of
Medicine, Tokyo, Japan 3 Institute for Research in biomedicine, bellinzona, switzerland
Oral 057 [Poster 271]
Cross talk between p63 and IRF6 in the regulation of keratinocyte proliferation
Moretti f 1 , spallone G 1 , botti e 1 , Merlo G 2 , Chimenti s 1 , alemà s 3 , Guerrini l 4 , Costanzo a 1 1 Dept of
Dermatology University of Rome Tor Vergata, Italy 2 Molecular biotechnology Center, DTI, University of Turin,
Italy 3 Cellular biology Institute, CnR, Rome, Italy 4 Cellular and Developmental biology, University of Milan, Italy
Oral 058 [Poster 272]
Mutations in either the OSMR or IL31RA genes underlie familial primary cutaneous amyloidosis
Tsai s 1 , lin M 2 , lee D 3 , McGrath J 4 1 national Health Research Institutes, Zhunan, Miaoli County, Taiwan
2 national Yang-Ming University, Taipei, Taiwan 3 Taipei Veterans General Hospital, Taipei, Taiwan 4 st John’s
Institute of Dermatology, london, UK
Oral 059 [Poster 273]
Microarray profiling in EEC ectodermal dysplasia syndrome skin reveals increased fatty acid-binding protein
FABP7 and reduced hair/nail keratin gene expression
Clements se, Techanukul T, Mellerio Je, McGrath Ja st Johns Institute of Dermatology, london, UK
Oral 060 [Poster 274]
High-throughput mutation profiling of CTCL samples using OncoMap
oberholzer Pa 1 , Karpova Mb 2 , Zipser MC 2 , lin WM 3 , Girardi M 3 , MacConaill le 1 , Kehoe sM 4 , Garraway la 1 ,
Dummer R 2 1 broad Inst of MIT & Harvard, Cambridge, Usa 2 Univ Hospital of Zurich, switzerland 3 Yale Univ
school of Medicine, new Haven, Usa 4 Dana-farber Cancer Inst, boston, Usa
17
CONCURRENT
SESSIONS

CONCURRENT
SESSIONS
CONCURRENT SESSION V: Epidermis and Hair Structure and Function
Saturday 12 September 2009, 08.45-10.15
KAPOSI ROOM
Chairs: Ralph Paus, Eli Sprecher
Talk duration is 8 minutes plus 2 minutes questions.
Oral 061 [Poster 395]
The role of γ1 chain containing laminins for the formation and function of the dermo-epidermal basement
membrane
fleger-Weckmann a 1 , bechtel M 1 , Reibetanz M 1 , Chen Zl 2 , smyth n 3 , nischt R 1 1 Dermatology Department,
Univ of Cologne, Germany 2 Rockefeller University, new York, Usa 3 school of biological science, University of
southampton, UK
Oral 062 [Poster 396]
MicroRNAs regulation of keratinocytes differentiation during human skin embryogenesis
nissan X, Denis J, saidani M, lemaitre G, Peschanski M, baldeschi C InseRM U861, evry, france
Oral 063 [Poster 397]
Targeted deletion of DNase1L2 leads to defective degradation of nuclear DNA in hairs and nails
fischer H 1 , Jäger K 1 , Rossiter H 1 , szabo s 1 , Hermann M 2 , Tobin DJ 3 , Popescu C 4 , Wagner ef 5 , Tschachler e 1 ,
eckhart l 1 1 Medical University of Vienna, Department of Dermatology, austria 2 Max f. Perutz laboratories,
Vienna, austria 3 Center for skin sciences, school of life sciences, Univ of bradford, austria 4 DWI an der
RWTH-aachen University, Germany 5 spanish national Cancer Centre, Madrid, spain
Oral 064 [Poster 398]
AKT-dependent PP2A activity is required for epidermal barrier formation during late epidermal development
o’shaughnessy Rf 1 , Welti JC 2 , byrne C 2 1 UCl Institiute of Child Health, london, United Kingdom 2 Centre for
Cutaneous Research, Institute of Cell and Molecular science, barts and the london, london, United Kingdom
Oral 065 [Poster 332]
Protein kinase C and AP-1-dependent upregulation of miR-203 is required for keratinocyte differentiation
sonkoly e 1 , loriè eP 2 , Törmä H 2 , Kato M 3 , ståhle M 1 , Pivarcsi a 1 1 Molecular Derm Res Group, stockholm,
sweden 2 Dept of Medical sciences, Uppsala Univ, sweden 3 Dept of exp Pathology, Univ of Tsukuba, Japan
Oral 066 [Poster 333]
IGFBP7, a biomarker deficient in psoriatic plaques and induced by UVB phototherapy, regulates keratinocyte
proliferation, differentiation and apoptosis
nousbeck J 1 , sarig o 2 , avidan n 3 , Indelman M 4 , bergman R 4 , Ramon M 4 , enk C 5 , sprecher e 6 1 Technion-
Israel Institute of Technology, Tel aviv sourasky Medical Center, Haifa, Tel aviv, Israel 2 Tel aviv sourasky
Medical Center, Tel aviv, Israel 3 Technion-Israel Institute of Technology, Haifa, Israel 4 Rambam Health Care
Campus, Haifa, Israel 5 Hadassah Hebrew University Medical school, Jerusalem, Israel 6 Tel aviv sourasky
Medical Center, Technion-Israel Institute of Technology, Tel aviv, Haifa, Israel
Oral 067 [Poster 334]
Identification of Spink6 - a widely-expressed and selective Kallikrein-related Peptidase Inhibitor
Meyer-Hoffert U 1 , Kantyka T 2 , Hansmann b 1 , Gläser R 1 , schröder JM 1 1 Department of Dermatology, Kiel,
Germany 2 Department of biochemistry, Krakow, Poland
Oral 068 [Poster 335]
Flaky tail mouse as a possible model of atopic dermatitis
Moniaga C 1 , Chikuma M 1 , Kawasaki H 2 , nakajima s 1 , Tanizaki H 1 , egawa G 1 , Honda T 1 , amagai M 2 , Miyachi
Y 1 , Kabashima K 1 1 Kyoto University Graduate school of Medicine, Japan 2 Keio University school of Medicine
Tokyo, Japan
Oral 069 [Poster 336]
Increased murine Beta-defensin-1, -3, and -14 expression after acute and chronic skin barrier disruption is
induced by cytokines and growth factors
Hinrichsen K 1 , Meingassner J 2 , Harder J 1 , Proksch e 1 1 University Hospital Kiel, Kiel, Germany 2 novartis
Institut for bioMedical Research, Vienna, austria
18

CONCURRENT SESSION VI: Carcinogenesis and Angiogenesis
Saturday 12 September 2009, 08.45-10.15
GRUBY ROOM
Chairs: Véronique Delmas, Reinhard Dummer
Talk duration is 8 minutes plus 2 minutes questions.
Oral 070 [Poster 459]
Promotion of lymphatic integrity by Angiopoietin-1
Kajiya K 1 , Kidoya H 2 , sawane M 1 , Yamanishi H 1 , Takakura n 2 1 shiseido Innovative science Research &
Development Center, Yokohama, Japan 2 osaka University, Japan
Oral 071 [Poster 460]
Pregnancy promotes melanoma lymph node invasion by enhancing VEGF dependent lymphangiogenesis
Khosrotehrani K 1 , nguyen Huu s 1 , Prignon a 1 , oster M 1 , avril Mf 2 , boitier f 2 , aractingi s 1 1 Pierre et Marie
Curie University-Paris6, Paris, france 2 Tarnier Hospital, Paris, france
Oral 072 [421]
Epithelial-mesenchymal transition (EMT)-like phenotype in GnT-V transgenic
Ishikawa a, Terao M, nakahara s, Kimura a, Moriwaki K, Murota H, Taniguchi n, Miyoshi e, Katayama I osaka
University, suita-shi, Japan
Oral 073 [Poster 422]
Tumor-stroma interaction is essential in a primary human in vitro skin cancer model using a human cancerassociated
dermal microenvironment
Commandeur s, De Gruijl fR, Willemze R, Tensen CP, elghalbzouri a leiden University Medical Center, leiden,
netherlands
Oral 074 [Poster 423]
MK2 regulates the early stages of skin tumor promotion
Johansen C 1 , Vestergaard C 1 , Kragballe K 1 , Ronkina n 2 , bohlmann l 2 , Kollias G 3 , Gaestel M 2 , Iversen l1
1 aarhus University Hospital, aarhus C, Denmark 2 Hannover Medical school, Hannover, Germany 3 biomedical
sciences Research Center “alexander fleming”, Vari, Greece
Oral 075 [Poster 424]
RAGE signaling promotes tumor-angiogenesis and controls endothelial cell-specific immune cell recruitment
Gebhardt C 1 , Kiessling f 2 , Delorme s 3 , nawroth PP 1 , bierhaus a 1 , arnold b 3 , enk aH 1 , angel P 3 1 University
Hospital Heidelberg, Germany 2 University Hospital aachen, Germany 3 German Cancer Research Center (DKfZ),
Heidelberg, Germany
Oral 076 [Poster 425]
Mice Lacking MSK1 and MSK2 Show Decreased Skin Tumor Development In a Two Stage Chemical
Carcinogenesis Model
Chang s 1 , Iversen l 1 , arthur Js 2 , Kragballe K 1 , Johansen C 1 1 aarhus University Hospital, aarhus C, Denmark
2 University of Dundee, Dundee, United Kingdom
Oral 077 [Poster 426]
Quiescent cultured keratinocytes derived from squamous cell carcinoma retain a cancer-specific gene
expression signature capable of differentiating squamous cell carcinoma from normal skin in vivo
Pourreyron C 1 , foerster J 1 , Hogan C 1 , Purdie K 2 , bruckner-Tuderman l 3 , Proby C 1 , McGrath Ja 4 , leigh IM 1 ,
south aP 1 1 University of Dundee, UK 2 Cancer Research UK, london, 3 Univ of freiburg, Germany 4 University of
london, UK
Oral 078 [Poster 427]
Effects of the immunosuppressant rapamycin on skin carcinoma formation by chronic UV exposure
Voskamp P 1 , Koehl Ge 2 , Rebel HG 1 , bouwes bavinck Jn 1 , Geissler eK 2 , De Gruijl fR 1 1 leiden University
Medical Center, netherlands 2 University of Regensburg, Germany
19
CONCURRENT
SESSIONS

CONCURRENT
SESSIONS
CONCURRENT SESSION VII: Cell Adhesion, Matrix Biology and Growth Factors
Saturday 12 September 2009, 11.15-12.45
KAPOSI ROOM
Chairs: Johann Bauer, Cornelia Mauch
Talk duration is 8 minutes plus 2 minutes questions.
Oral 079 [Poster 472]
Novel fibronectin (FN) peptide protects adult human dermal fibroblasts (AHDF) from oxidative- and cytokineinduced
death and inhibits burn injury progression
Clark R, Macri l, Tonnesen T stony brook University, stony brook, Usa
Oral 080 [Poster 473]
The role of the receptor tyrosine kinase, Axl, in intercellular adhesion and signalling in cutaneous squamous
cell carcinoma
Cichon Ma, Papadakis es, Mackenzie IC, o’Toole ea barts and the london sMD, Queen Mary University of
london, london, United Kingdom
Oral 081 [Poster 474]
The mTOR inhibitor everolimus is a potent suppressor of collagen synthesis in vitro and skin and lung fibrosis
in mice - perspectives for new treatments of fibrotic diseases
böhm M 1 , Kokot a 1 , luger Ta 1 , scharffetter-Kochanek K 2 , sindrilaru a 2 1 University of Münster, Dept of
Dermatology, Münster, Germany 2 University of Ulm, Dept of Dermatology and allergic Diseases, Ulm, Germany
Oral 082 [Poster 475]
Laminin-332 and perlecan are crucial regulators of the plasminogen activation cascade: implications for
epithelial homeostasis and tumor formation
Gagnoux-Palacios l, botta a, Delteil f, estrach s, Meneguzzi G InseRM, nice, france
Oral 083 [Poster 500]
Dimethylfumarate inhibits Macrophage Inhibitory Factor induced proliferation of keratinocytes
Gesser b, Rasmussen MK, Rosada C, Johansen C, Kjellerup K, Kragballe K, Iversen l aarhus University
Hospital, aarhus C, Denmark
Oral 084 [Poster 501]
STAT4 serine phosphorylation during keratinocyte mitosis
ferreli C, Pickard C, august s, buggy Y, ardern-Jones M, friedmann Ps, Healy e University of southampton,
southampton, United Kingdom
Oral 085 [Poster 502]
Regulation of tissue inhibitor of matrix metalloproteinases-1 and -3 in fibroblasts by mitogen-activated
protein kinase pathways and zinc binding protein 89
Hieta n 1 , ala-aho R 2 , Merchant Jl 3 , Kähäri VM 2 1 Turku University Hospital, Turku, finland 2 University of
Turku, Turku, finland 3 University of Michigan, ann arbor, Usa
Oral 086 [Poster 476]
Collagen-binding integrins alpha2beta1 and alpha11beta1 - key determinants of scar matrix remodeling?
Hallinger R 1 , blumbach K 1 , Gullberg D 2 , Krieg T 1 , eckes b 1 1 Dermatology, Univ of Cologne, Cologne, Germany
2 Physiology, Univ of bergen, bergen, norway
Oral 087 [Poster 477]
Collagen XVII in hemidesmosomes is involved in keratinocyte-collagen IV adhesion and p38-MAPK-dependent
cell migration and signaling
McMillan JR 1 , Qiao H 2 , shibaki a 2 , long Ha 2 , Wang G 2 , nishie W 2 , akiyama M 2 , shimizu H 2 1 Hokkaido
University, The University of Queensland, Herston, brisbane, australia 2 Hokkaido University, sapporo, Japan
20

CONCURRENT SESSION VIII: Auto-Immunity, Inflammation and Infectious Diseases
Saturday 12 September 2009, 11.15-12.45
GRUBY ROOM
Chairs: Masa Amagai, Vincent Piguet
Talk duration is 8 minutes plus 2 minutes questions.
523 [Oral 088]
Identification of a novel skin homing Vγ9Vδ2 T cell subset and its potential implication in the
immunopathogenesis of psoriasis
laggner U, Di Meglio P, Hundhausen C, Perera G, smith CH, barker J, Hayday a, nestle f King’s College
london, london, United Kingdom
Oral 089 [Poster 524]
Non-allergenic mediators from pollen induce mast cell dependent skin inflammation
Metz M 1 , Gilles s 2 , Heydrich s 1 , Traidl-Hoffmann C 2 , Maurer M 1 1 Charité - Universitätsmedizin berlin, berlin,
Germany 2 ZaUM-Center for allergy and environment, HelmholtzCenter/Technische Universität München,
Munich, Germany
Oral 090 [Poster 600]
Mast cells regulate the magnitude and the cytokine microenvironment in HSV infection
aoki R 1 , Kawamura T 1 , Goshima f 2 , nishiyama Y 2 , shimada s 1 1 University of Yamanashi, Yamanashi, Japan
2 nagoya University Graduate school of Medicine, nagoya, Japan
Oral 091 [Poster 525]
Identification of a novel receptor For S100a8/A9, a key mediator of inflammation in human skin
Hibino T 1 , sakaguchi M 2, ehama R 1 , Yamamoto M 3 , Motoyama n 1 1 shiseido Research Center, Yokohama,
Japan 2 okayama University Graduate school of Medicine, okayama, Japan 3 Tokyo Medical University, Dept of
Dermatology, Tokyo, Japan
Oral 092 [Poster 526]
Characterization of functions and egress mechanism on skin regulatory T cell using Kaede-transgenic mice
Honda T 1 , Tomura M 2 , otsuka a 1 , Tanizaki H 1 , Kanagawa o 2 , Miyachi Y 1 , Kabashima K 1 1 Kyoto University,
Kyoto, Japan 2 RIKen, Yokohama, Japan
Oral 093 [Poster 527]
Isolation and characterization of autoreactive human Mabs from pemphigus vulgaris patients
Di Zenzo G 1 , Di lullo G 2 , Calabresi V 1 , sinistro a 1 , Didona b 3 , Cianchini G 4 , eming R 5 , Hertl M 5 , Zambruno
G 1 , lanzavecchia a 2 1 Molecular and Cell biology laboratory, IDI-IRCCs, Rome, Italy 2 Inst for Research in
biomedicine-IRb, bellinzona, switzerland 3 I Derm Division, IDI-IRCCs, Rome, Italy 4 V Dermatology Division,
IDI-IRCCs, Rome, Italy 5 Dept of Dermatology & allergology, Philipp’s University, Marburg, Germany
Oral 094 [Poster 528]
Self-peptide treatment prolongs survival in murine autoimmunity via CD8/Valpha2-(co)receptor tuning and
reduction of both IL2-/IL7-induced STAT5-signaling and effector cytokines
Gutermuth J, nograles K, nelson e, Miyagawa f, Cho YH, Katz sI national Institutes of Health, bethesda, Usa
Oral 095 [Poster 529]
Association study between auto-immunity genetic markers, melanoma susceptibility and prognosis
Guedj M 1 , Descamps V 2 , Dieude P 2 , Dupin n 3 , Wolkenstein P 4 , saiag P 5 , lebbe C 6 , basset-seguin n 7 ,
Grandchamp b 2 , soufir n 2 1 Programme CIT 2 Hôp bichat Claude bernard 4 Hôp Tarnier 5 Hôp Henri Mondor
6 Hôp ambroise Paré boulogne billancourt 7 Hôp saint louis: france
Oral 096 [Poster 530]
T cell labelling modalities for non invasisve in vivo T cell tracking
Griessinger C, bukala D, Wiehr s, ehrlichmann s, Kehlbach R, bantleon R, Reichl G, Pichler b, Röcken M,
Kneilling M eberhard Karls University, Tübingen, Germany
21
CONCURRENT
SESSIONS

WEDNESDAY 9 SEPTEMBER 2009
DAY-BY-DAY PROGRAM
Time Session Room Program
12.00-19.00 Registration
14.00-18.00 PXe symposium nékám p 28
14.00-18.00 european Immunodermatology society
(eIs)
14.00-18.00 european society for Pigment Cell
Research (esPCR)
14.00-18.00 european epidermal barrier Research
network (e2bRn)
14.00-19.00 Pemphigus Consensus Meeting
(Invitation only)
15.00-19.00 esDR board Meeting I
(Invitation only)
18.00- eIs board Meeting
(Invitation only)
22
semmelweis p 29
Gruby p 30
Kaposi p 31
VIP suite -
Dermatology
Dept
-
seminar 1 -

DAY-BY-DAY PROGRAM
Time Session Room Program
07.00-19.00 Registration
08.00-14.00 Poster Mounting
08.00-10.30 european epidermal barrier Research
network (e2bRn)
23
Kaposi p 31
08.00-10.30 neurobiology of the skin nékám p 32
08.00-10.30 european society of Dermatopathology
(esDP)
08.00-10.30 european Dermato-epidemiology
network (eDen)
10.30-11.00 Coffee break
Gruby p 33
semmelweis p 34
11.00-12.30 esDR Postgraduate Course semmelweis p 9
12.30-14.00 skin Cell Migration/Invasion workshop Kaposi p 26
12.30-14.00 JDs editorial board Meeting nékám
13.00-14.00 biotest sponsored symposium Gruby p 36
14.00-16.00 Plenary session I (8 presentations) semmelweis p 11
16.00-16.30 Coffee break
16.30-17.00 esDR Guest lecture - Cancer
(Moshe oren)
Introduced by antonio Costanzo
semmelweis p 9
17.00-18.30 Concurrent session I: Immunology semmelweis p 14
17.00-18.30 Concurrent session II: Clinical
Investigation and epidemiology
17.00-18.30 Concurrent session III: Photobiology,
Pigmentation and Melanoma
17.00-18.30 Concurrent session IV: Genetic
Disease, Gene expression and Gene
Therapy
Kaposi p 15
Gruby p 16
nékám p 17
18.30-19.00 Welcome Ceremony semmelweis
19.00-22.00 Welcome Reception/Poster Viewing I pp 9, 41
THURSDAY 10 SEPTEMBER 2009

FRIDAY 11 SEPTEMBER 2009
DAY-BY-DAY PROGRAM
Time Session Room Program
06.45-07.45 Run for atopic Dermatitis orczy Garden p 8
07.00-08.30 International Pemphigoid Consensus
meeting (invitation only)
24
nékám
08.30-11.00 Plenary session II (10 presentations) semmelweis p 12
11.00-11.30 Coffee break
11.30-12.00 Merck serono lecture (Ron Germain)
Introduced by alexander enk
12.00-12.30 René Touraine lecture (sabine Werner)
Introduced by louis Dubertret
12.30-14.00 JID editorial board nékám
semmelweis p 9
semmelweis p 9
12.30-14.00 Galderma sponsored symposium Kaposi p 37
14.00-15.00 esRf scientific Review Committee
(invitation only)
seminar 1
14.00-15.30 Poster Viewing II Poster area p 41
15.30-16.00 Coffee break
16.00-16.10 Presentation of esDR Honorary
Memberships
16.10-16.40 Rudi Cormane lecture (lars french)
Introduced by Reinhard Dummer
semmelweis p 44
semmelweis p 9
16.40-16.50 Poster Prizes semmelweis
16.50-16.55 esRf new Investigator awards semmelweis
16.55-17.00 JsID/esDR Collegialty awards semmelweis
17.00-18.30 Plenary session III (6 presentations) semmelweis p 13
18.30-19.15 esDR annual General assembly semmelweis
19.30- esDR 2009 Hungarian evening orczy Garden p 8

DAY-BY-DAY PROGRAM
Time Session Room Program
07.45-08.45 esDR/sID/JsID liaison Committee
Meeting (invitation only)
08.45-10.15 Concurrent session V: epidermis and
Hair structure and function
08.45-10.15 Concurrent session VI: Carcniogenesis
and angiogenesis
25
seminar 1
Kaposi p 18
Gruby p 19
08.45-10.15 Clinical saturday I semmelweis p 9
10.15-11.15 Poster Viewing III (with Poster Walks
and coffee break)
11.15-12.45 Concurrent session VII: Cell adhesion,
Matrix biology and Growth factors
11.15-12.45 Concurrent session VIII: auto-
Immunity, Inflammation and Infectious
Diseases
p 41
Kaposi p 20
Gruby p 21
11.15-12.45 Clinical saturday II semmelweis p 9
12.45-14.15 eastern european session nékám p 35
12.45-14.15 CTCl Workshop
(sponsored by Cephalon)
Kaposi p 27
14.15-15.15 2009 esDR Meeting Digest semmelweis p 9
15.15-15.30 Closing Ceremony semmelweis
15.30-16.30 esDR board Meeting II
(invitation only)
seminar 1
SATURDAY 12 SEPTEMBER 2009

SPECIAL
WORKSHOPS
SKIN CELL MIGRATION AND INVASION
Thursday 10 September 2009, 12.30-14.00
KAPOSI ROOM
Chair: Véronique Delmas
Program
12.30-12.32 Introduction by Chair
12.32-12.54 Role of E-Cadherin in normal and pathological melanocyte development
Véronique Delmas (orsay, france)
12.54-13.16 Regulation of Integrin-dependent cell migration by cytoplasmic adapter
proteins
bernhard Wehrle-Haller (Geneva, switzerland)
13.16-13.38 Functions of Rac1 in epidermal wound healing and epithelial skin tumor
invasion
Ingo Haase (Cologne, Germany)
13.38-14.00 Functions of MMPs in skin invasion process
Cornelia Mauch (Cologne, Germany)
This Workshop is open to all esDR meeting participants.
noTes.............................................................................................................................................................................
........................................................................................................................................................................................
........................................................................................................................................................................................
........................................................................................................................................................................................
........................................................................................................................................................................................
........................................................................................................................................................................................
........................................................................................................................................................................................
........................................................................................................................................................................................
........................................................................................................................................................................................
........................................................................................................................................................................................
........................................................................................................................................................................................
........................................................................................................................................................................................
........................................................................................................................................................................................
........................................................................................................................................................................................
........................................................................................................................................................................................
........................................................................................................................................................................................
........................................................................................................................................................................................
........................................................................................................................................................................................
........................................................................................................................................................................................
........................................................................................................................................................................................
........................................................................................................................................................................................
........................................................................................................................................................................................
........................................................................................................................................................................................
........................................................................................................................................................................................
........................................................................................................................................................................................
........................................................................................................................................................................................
........................................................................................................................................................................................
........................................................................................................................................................................................
........................................................................................................................................................................................
........................................................................................................................................................................................
........................................................................................................................................................................................
26

CTCL
Saturday 12 September 2009, 12.45-14.15
KAPOSI ROOM
Chairs: Martine Bagot, Reinhard Dummer
Program
12.45-13.05 French Bexarotene Survey: ORELY, Baseline of 106 Patients with CTCL
Christophe bedane (limoges, france)
13.05-13.25 EORTC Clinical Trials: How to Create an Intelligent Platform!
Martine bagot (Paris, france)
13.25-13.45 Targeted Therapies in CTCL: Do They Hit the Target?
Reinhard Dummer (Zurich, switzerland)
13.45-14.05 Challenging Clinical Cases
Marta Marschalko, budapest
14.05-14.15 Round Table Discussion
This Workshop is open to all esDR meeting participants.
27
Generously supported by
noTes............................................................................................................................................................................
........................................................................................................................................................................................
........................................................................................................................................................................................
........................................................................................................................................................................................
........................................................................................................................................................................................
........................................................................................................................................................................................
........................................................................................................................................................................................
........................................................................................................................................................................................
........................................................................................................................................................................................
........................................................................................................................................................................................
........................................................................................................................................................................................
........................................................................................................................................................................................
........................................................................................................................................................................................
........................................................................................................................................................................................
........................................................................................................................................................................................
........................................................................................................................................................................................
........................................................................................................................................................................................
........................................................................................................................................................................................
........................................................................................................................................................................................
........................................................................................................................................................................................
........................................................................................................................................................................................
........................................................................................................................................................................................
........................................................................................................................................................................................
........................................................................................................................................................................................
........................................................................................................................................................................................
........................................................................................................................................................................................
........................................................................................................................................................................................
........................................................................................................................................................................................
........................................................................................................................................................................................
........................................................................................................................................................................................
........................................................................................................................................................................................
SPECIAL
WORKSHOPS

PXE
SYMPOSIUM
SATELLITE MEETING: PXE SYMPOSIUM
Wednesday 9 September 2009, 14.00-18.00
NEKAM ROOM
Sponsored by PXE International
note: To partially offset the costs of this symposium, a modest fee of euro 50 is requested
from those participants who are not registered for the main esDR meeting. This fee includes
Hungarian wine reception at the conclusion of the symposium. This fee should be paid at the
main esDR registration desk by cash or credit card.
Chairs: andras Váradi, sharon Terry and Jouni Uitto
Program
14.00-14.30 Introduction to PXE – The Role of Patient Advocacy Organisations
Patrick Terry (PXe International)
14.30-15.00 Clinical and Morphological Observations in PXE
Ivonne Pasquali-Ronchetti (University of Modena)
15.00-15.30 The ABCC6 Transporter System - Perturbations in PXE
andras Váradi (Hungarian academy of sciences)
15.30-16.00 Pathomechanisms of PXE
Jouni Uitto (Thomas Jefferson University)
16.00-18.00 Roundtable Discussion: Prospects of Therapies for PXE
Invited discussants and all participants
18.00 Hungarian Wine Reception
noTes.............................................................................................................................................................................
........................................................................................................................................................................................
........................................................................................................................................................................................
........................................................................................................................................................................................
........................................................................................................................................................................................
........................................................................................................................................................................................
........................................................................................................................................................................................
........................................................................................................................................................................................
........................................................................................................................................................................................
........................................................................................................................................................................................
........................................................................................................................................................................................
........................................................................................................................................................................................
........................................................................................................................................................................................
........................................................................................................................................................................................
........................................................................................................................................................................................
........................................................................................................................................................................................
........................................................................................................................................................................................
........................................................................................................................................................................................
........................................................................................................................................................................................
........................................................................................................................................................................................
........................................................................................................................................................................................
........................................................................................................................................................................................
........................................................................................................................................................................................
........................................................................................................................................................................................
........................................................................................................................................................................................
........................................................................................................................................................................................
........................................................................................................................................................................................
........................................................................................................................................................................................
28

SATELLITE MEETING: EUROPEAN IMMUNODERMATOLOGY SOCIETY (EIS)
Wednesday 9 September 2009, 14.00-18.00
SEMMELWEIS ROOM
The european Immunodermatology society (eIs) meeting will be held at the esDR meeting
venue and is open to all registered esDR Meeting participants.
Program
14.00-14.05 Welcome
Richard Groves (london), Jan simon (leipzig)
Session 1
14.05-14.20 Abscence of CCR4 Exacerbates Skin Inflammation in the Oxazolone Induced Contact
Hypersensitivity Model
sari lehtimäki (Helsinki)
14.20-14.35 ATP is a tissue site specific activator of the suppressive capacity of naïve regulatory T cells
during contact hypersensitivity reactions
sabine Ring (Heidelberg)
14.35-14.50 Cytotoxic activity of invariant NKT cells in human allergic contact dermatitis
anna balato (naples)
14.50-15.05 Flow cytometric analysis of peripheral invariant NKT cells in patients with atopic dermatitis
edit Gyimesi (Debrecen)
15.05-15.20 IL-17 and IL-22 producing Th17 cells induce protein contact dermatitis
Ivana Glocova (Tübingen)
15.20-15.35 Impaired allergic contact dermatitis response to DNCB in atopic dermatitis (AD) is enhanced by
filaggrin loss of function variants
louise newell (southampton)
15.35-15.50 Induction of regulatory T cells by immature epidermal Langerhans cells upon oral
glucocorticosteroid treatment
Georg stary (Vienna)
15.50-16.20 Coffee Break
Session 2
16.20-16.35 The characterisation of regulatory and effector FOXP3 expressing T cell populations during a
human cutaneous antigen-specific memory response in vivo
elaine agius (london)
16.35-16.50 Participation of newly-identified IL-1 family members in the pathogenesis of psoriasis
andrew Johnston (london)
16.50-17.05 Production of Tolerance-Inducing Molecules for Type XVII Collagen for Gene Therapy in
Junctional Epidermolysis Bullosa Patients
Monika ettinger (salzburg)
17.05-17.20 Th1/TH17 cells amplify human contact hypersensitivity by licensing Th1to kill autologous
keratinocytes in a ICAM-1 dependent antigen non specific manner
andrea Cavani (Rome)
17.20-17.35 CGRP induces ex vivo upregulation of epidermal TLR9 expression and LL37 gene-expression
ewout baerveldt (Rotterdam)
17.35-17.50 The role of interleukin-1 and the interleukin-1 receptors in regulatory T cell functions
ferenc Kovács-sólyom (szeged)
17.50-18.00 Concluding Remarks
29
EIS MEETING

ESPCR
SYMPOSIUM
SATELLITE SYMPOSIUM: EUROPEAN SOCIETY FOR PIGMENT CELL RESEARCH (ESPCR)
Wednesday 9 September 2009, 14.00-18.00
GRUBY ROOM
The esPCR symposium will be held at the esDR meeting venue and is open to all registered
esDR Meeting participants.
Program
14.00-14.15 Introduction and Overall Presentation: “To Tan or not to Tan? This is the Symposium”
Mauro Picardo (Rome)
14.15-14.35 New Molecular Aspects in the Regulation of Skin Pigmentation
Robert ballotti (nice)
14.35-14.55 UVB, Tanning and Anti-oxidative Effector Mechanisms induced by alpha-melanocyte
Stimulating Hormone
Markus bohm (Münster)
14.55-15.15 Melanin Transfer in Human Skin Cells in vitro: A Fascinating World beyond the Dendrite
Des Tobin(bradford)
Free Communications 1 & 2 (10 minutes + 2 minutes discussion)
15.20-15.32 UVB regulation is both direct and indirect on TRP-1 mRNA, a melanocyte differentiation
marker in human melanocytes
bernadett Kormos (szeged)
15.32-15.44 The role of Wnt/b-catenin pathway in melanocytes differentiation
barbara bellei (Rome)
15.44-15.55 Break
15.55-16.15 Fibroblasts Regulate the Basal Pigmentation pf the Skin in vitro and in vivo
Muriel Cario-andré (bordeaux)
16.15-16.35 From Pigmentation to Melanoma: The Role of SOX9 in Melanocytes
Thierry Passeron (nice)
16.35-16.55 Albinism in Tanning
lluis Montoliu (Madrid)
16.55-17.15 From Proliferation to Pigmentation
lionel larue (Paris)
Free Communications 3-5 (10 minutes + 2 minutes discussion)
17.15-17.27 What are the objective determinants of tanning (facultative pigmentation)?
Terence Wong (edinburgh)
17.27-17.39 An interplay between TGF-beta and PKA signaling inversely regulates the melanogenic
differentiation program in melanoma cells
alain Mauviel (Paris)
17.39-17.51 Evaluation of Ethosomes for Delivery of siRNA into Cultured Primary Melanocytes and Skin
Mireille Van Gele (Ghent)
17.51-18.00 Concluding Remarks
30

SATELLITE MEETING: 7TH EUROPEAN EPIDERMAL BARRIER RESEARCH NETWORK (E2BRN)
9-10 September 2009
KAPOSI ROOM
The 7th european epidermal barrier Research network (e2bRn) meeting will be held at the
esDR meeting venue and is open to all registered esDR Meeting participants.
Scientific Organising Committee: PD Dr. Johanna brandner, Prof. Carien niessen, Prof. Joost
schalkwijk
Program
Wednesday 9 September 2009
Young Investigator Session (PhD/Postdocs)
Chair: Michel simon (Toulouse, france)
13.30-13.35 Introduction
13.35-13.50 Active transdermal protein delivery through photoinduced pressure waves
Gonzalo f.f. sa (Coimbra, Portugal)
13.50-14.05 Comparison of Microdialysis and Microperfusion for efficient in vivo research on dermal
barrier function and penetration
Manfred bodenlenz (Graz, austria)
14.05-14.20 Evaluation of the role of autophagy in epidermal keratinocytes
Heidemarie Rossiter (Vienna, austria)
14.20-14.35 Lysyl Oxidase silencing impairs keratinocyte differentiation
G. le Provost (lyon, france)
14.35-14.50 Coffee Break
14.50-15.05 Alteration of tight junction proteins is an early event in psoriasis and involves proinflammatory
cytokines
nina Kirschner (Hamburg, Germany)
15.05-15.20 Decreased Filaggrin expression results in impaired epidermal barrier function in ichthyosis
vulgaris
Robert Gruber (Innsbruck, austria)
15.20-15.35 Deletion of the LCE3B and LCE3C Genes on 1q21 is not associated with atopic dermatitis
Judith bergboer (nijmegen, netherlands)
15.35-15.50 Lef1 mediated regulation of sebaceous gland lipid metabolism regulates skin barrier function
Catherin niemann (Cologne, Germany)
15.50-15.55 Concluding Remarks
15.55-16.30 Coffee Break
Workshop on Reconstructed Skin Models as Alternatives to Animal Experiments
Chair: leopold eckhart (Vienna, austria)
16.30-17.00 Barrier Properties of Human Skin Equivalents
Joke bouwstra (leiden, netherlands)
17.00-17.30 Use of gene silencing in reconstructed skin models
Michael Mildner (Vienna, austria)
17.30-18.00 In vitro reconstructed skin models: applications in epidermal biology and inflammation
Joost schalkwijk (nijmegen, netherlands)
Thursday 10 September 2009
Senior Member Session
Chair: Johanna M. brandner (Hamburg, Germany)
09.00-09.30 The fate of cell-cell junctions upon cornification and their impact on desquamation
Marek Haftek (lyon, france)
09.30-10.00 The role of intercellular adhesion and polarity in the regulation of the skin barrier
Carien niessen (Cologne, Germany)
10.00-10.30 Degradation of nucleic acids at the epidermal barrier
leopold eckhart (Vienna, austria)
10.30-10.50 Coffee Break
10.50-12.30 E2BRN General Assembly
31
E2BRN MEETING

NEUROBIOLOGY OF THE SKIN
SYMPOSIUM
SATELLITE SYMPOSIUM: NEUROBIOLOGY OF THE SKIN
Thursday 10 September 2009, 08.00-10.30
NEKAM ROOM
The neurobiology of the skin symposium will be held at the esDR meeting venue and is open to
all registered esDR Meeting participants.
Chairs: anna Zalewska (lodz, Poland), Marcus Maurer (berlin, Germany)
Program
Neurotrophins in healthy and diseased skin
C Pincelli (Modena, Italy)
Skin mast cells and cutaneous sensory nerves – duo infernale of pruritus
M Maurer (berlin, Germany)
Neuroreceptors involved in Pruriception
s ständer (Munich, Germany)
Alpha-MSH and fragments: mediators of neuroinflammation with a therapeutic potential
T luger (Munich, Germany)
Catecholamines and stress: implications for wound healing
RR Isseroff (sacremento, Usa)
fMRI brain scan studies in dermatology
CeM Griffiths (Manchester, UK)
Psychoneuroimmunology – clinical implications
W Glinski (Warsaw, Poland)
ItchyQol and CuQol – Novel instruments for measuring quality of life in patients with pruritic
skin disorders
M Metz (berlin, Germany)
noTes.............................................................................................................................................................................
........................................................................................................................................................................................
........................................................................................................................................................................................
........................................................................................................................................................................................
........................................................................................................................................................................................
........................................................................................................................................................................................
........................................................................................................................................................................................
........................................................................................................................................................................................
........................................................................................................................................................................................
........................................................................................................................................................................................
........................................................................................................................................................................................
........................................................................................................................................................................................
........................................................................................................................................................................................
........................................................................................................................................................................................
........................................................................................................................................................................................
........................................................................................................................................................................................
........................................................................................................................................................................................
........................................................................................................................................................................................
........................................................................................................................................................................................
........................................................................................................................................................................................
32

SATELLITE SYMPOSIUM: EUROPEAN SOCIETY FOR DERMATOPATHOLOGY (ESDP)
Thursday 10 September 2009, 08.00-10.30
GRUBY ROOM
The esDP symposium will be held at the esDR meeting venue and is open to all registered
esDR Meeting participants.
Chair: Gürkan Kaya (Geneva, switzerland)
Program
08.00-08.05 Welcome
08.05-08.35 Role of calcium and NFAT signalling in sensing and responding to
environmental stress in the epidermis
nick Reynolds (newcastle)
08.35-09.05 Regulating malignant formation by T-cell cytokines
Martin Röcken (Tübingen)
09.05-09.35 Translational medicine: What the pharma industry wants from the
dermatopathologist
Conrad Hauser (Geneva)
09.35-10.05 Genomics of melanoma progression: Research without clinical
application?
József Tímár (budapest)
10.05-10.25 Panel Discussion
10.25-10.30 Concluding Remarks
noTes.............................................................................................................................................................................
........................................................................................................................................................................................
........................................................................................................................................................................................
........................................................................................................................................................................................
........................................................................................................................................................................................
........................................................................................................................................................................................
........................................................................................................................................................................................
........................................................................................................................................................................................
........................................................................................................................................................................................
........................................................................................................................................................................................
........................................................................................................................................................................................
........................................................................................................................................................................................
........................................................................................................................................................................................
........................................................................................................................................................................................
........................................................................................................................................................................................
........................................................................................................................................................................................
........................................................................................................................................................................................
........................................................................................................................................................................................
........................................................................................................................................................................................
........................................................................................................................................................................................
........................................................................................................................................................................................
........................................................................................................................................................................................
........................................................................................................................................................................................
........................................................................................................................................................................................
........................................................................................................................................................................................
........................................................................................................................................................................................
........................................................................................................................................................................................
........................................................................................................................................................................................
........................................................................................................................................................................................
33
ESDP
SYMPOSIUM

EDEN
MEETING
SATELLITE MEETING: EUROPEAN DERMATO-EPIDEMIOLOGY NETWORK (EDEN)
Thursday 10 September 2009, 08.00-10.30
SEMMELWEIS ROOM
The eDen Meeting will be held at the esDR meeting venue and is open to all registered esDR
Meeting participants.
Chair: PJ Coenraads (Groningen, The netherlands)
Program
08.00-08.05 Opening
PJ Coenraads (Groningen)
08.05-08.20 Changing delayed-type hypersensitizations to the standard series allergens over a decade at
the Zurich University Hospital
M Janach (Zurich)
08.20-08.35 A prospective case-controlled cohort study to assess pre-clinical cardiovascular disease in
patients with moderate to severe psoriasis
Cl Martyn-simmons (london)
08.35-08.50 Epidemiology of cutaneous melanoma in Austria 1996, preliminary results of a national
histopathology-based survey
K Rappersberger (Vienna)
08.50-09.05 Using a structured image database: how well can novices assign skin lesion images to the
correct diagnostic grouping
Jl Rees (edinburgh)
09.05-09.20 Use of the Day Reconstruction Method (DRM) as an experiential sampling tool to assess
subjective symptoms in atopic dermatitis
Jl Rees (edinburgh)
09.20-09.35 Prevalence of atopic dermatitis in urban and rural schools in Gabon and Ghana
aP lavrijsen (leiden)
09.35-09.50 Squamous cell carcinoma of the skin induces sustained considerable cost of care in organ
transplant recipients
C Rüegg (Zurich)
09.50-10.05 Ethnic variations in facial variations in facial skin neurosensitivity assessed by capsaicin
detection thresholds
R Jourdain (Clichy)
10.05-10.20 Analysis of risk factors in cutaneous malignant melanoma: an Italian population-based study
e Campione (Rome)
10.20-10.30 Concluding Remarks
PJ Coenraads (Groningen)
noTes.............................................................................................................................................................................
........................................................................................................................................................................................
........................................................................................................................................................................................
........................................................................................................................................................................................
........................................................................................................................................................................................
........................................................................................................................................................................................
........................................................................................................................................................................................
........................................................................................................................................................................................
........................................................................................................................................................................................
........................................................................................................................................................................................
........................................................................................................................................................................................
........................................................................................................................................................................................
........................................................................................................................................................................................
34

COMMON GOALS AND CHALLENGES IN DERMATOLOGIC RESEARCH IN EASTERN EUROPE
Saturday 12 September 2009, 12.45-14.15
NEKAM ROOM
Chairs: Stephen Katz, Sarolta Kárpáti
note: This session is open to all eastern european scientists and those with
an interest in the development of dermatological research in eastern europe.
Program
12.45-12.50 Introduction
12.50-13.10 Development of ESDR activities in Eastern Europe
sarolta Kárpáti (Hungary)
13.10-13.30 Common goals and challenges in Dermatologic Research
stephen Katz (Usa)
13.30-14.10 Open discussion with the participants
Moderator: norbert Wikonkal
14.10-14.15 Donation of the Nekam Plaquette
awarded to stephen Katz by the Hungarian Dermatological
society as recognition of his contribution to the development
of dermatology worldwide
noTes........................................................................................................................................................................
.................................................................................................................................................................................
..................................................................................................................................................................................
..................................................................................................................................................................................
..................................................................................................................................................................................
..................................................................................................................................................................................
..................................................................................................................................................................................
..................................................................................................................................................................................
..................................................................................................................................................................................
..................................................................................................................................................................................
..................................................................................................................................................................................
..................................................................................................................................................................................
..................................................................................................................................................................................
.................................................................................................................................................................................
..................................................................................................................................................................................
..................................................................................................................................................................................
..................................................................................................................................................................................
..................................................................................................................................................................................
..................................................................................................................................................................................
..................................................................................................................................................................................
..................................................................................................................................................................................
..................................................................................................................................................................................
..................................................................................................................................................................................
..................................................................................................................................................................................
..................................................................................................................................................................................
35
EASTERN EUROPE
SESSION

BIOTEST
SYMPOSIUM
INTRAVENOUS IMMUNOGLOBULINS IN DERMATOLOGICAL AUTOIMMUNE DISEASES
Thursday 10 September 2009, 13.00-14.00
GRUBY ROOM
Chairs: Alexander Enk (Heidelberg), Lars French (Zurich)
Program
European Guidelines on the use of High-Dose IVIG in Dermatology:
Indications and Therapy Management
alexander enk (Heidelberg)
IVIG 2009: Mechanisms of Action and their Role in the Treatment of
Autoimmune Diseases
beatrix Volc-Platzer (Vienna)
Toxic Epidermal Necrolysis: Current Understanding and Therapeutic
Possibilities
lars french (Zurich)
NOTES
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
36

ADVANCES IN ROSACEA RESEARCH
Friday 11 September 2009, 12.30-14.00
KAPOSI ROOM
Note: Lunch boxes will be provided to symposium participants.
Introduction
Rosacea is one of the most frequent diagnoses in dermatology. first, this chronic inflammatory skin disease clearly
has a genetic component which is of unknown origin as of yet. additionally, rosacea can be triggered by many
external/environmental factors such as ultraviolet radiation, spicy food, alcohol, stress, temperature changes
etc. It is interesting to note that - being a progressive chronic inflammatory skin disease - the development of
rosacea is characterized by multiple clinical conditions such as transient or persistent erythema, telangiectasia,
lymphedema and later fibrosis. Morphologically, rosacea is characterized by a lympho-monocytic infiltrate.
However, activated keratinocytes, fibroblasts and mast cell suggest that the pathophysiology of this disease is
very complex, and involves almost all skin and immune cells. That being said, rosacea appears to be also a very
good “model” for learning more about the complexity of neuro-immune interactions, dysregulated inflammatory
mechanisms and immunity, as well as vascular dysregulation during inflammation, and the development of
fibrotic processes during chronic inflammation.
Indeed, evidence is evolving that in chronic inflammatory diseases a close molecular and cellular interaction
exists between innate immune defence mechanisms, nerves, immune as well as blood and lymphatic endothelial
cells. It is important to highlight, that the treatment of this common disease is still unsatisfactory and which
demands a deeper understanding of the underlying mechanisms. Consequently, this symposium will focus
on understanding the molecular clusters of different body systems (immune, nervous, vascular, connective)
during chronic inflammatory processes, in order to find new strategies for the treatment of rosacea and other
inflammatory or fibrotic skin diseases.
Program
Introduction
Martin steinhoff (Germany/Usa)
Clinical Update on Rosacea
Martin schaller (Germany)
Innate Immune System in Rosacea
Jürgen schauber (Germany)
Role of the Vascular Symstem in Inflammatory Skin Diseases
Michael Detmar (switzerland)
Role and Mechanisms of Action of Activin in Wound Repair, Fibrosis and Skin Cancer
sabine Werner (switzerland)
Neuroimmunological Aspects of Rosacea
Martin steinhoff (Germany/Usa)
Questions & Answers/Closing Remarks
Martin steinhoff (Germany/Usa)
NOTES
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
37
GALDERMA
SYMPOSIUM

GENERAL
INFORMATION
GENERAL INFORMATION
THE MEETING VENUE
The 39th esDR annual Meeting is held from Wednesday 9 september to saturday 12 september 2009 at the
semmelweis University - soTe net, in budapest, Hungary. The University is located a few kilometres outside the
city centre and is easily accessible by public transport.
Address of Meeting Venue
semmelweis University - soTe net
nagyvárad tér 4
H-1089 budapest
Hungary
Getting to Semmelweis University - SOTE Net
The easiest way to get to the venue is by metro. Take the blue line (line 3) to the nagyvárad tér stop. When you
exit, you will see a tall building (semmelwies Medical University building). Walk towards this building. The esDR
meeting is located in the lecture complex adjacent to this building. Metro tickets are available for sale at the
meeting venue.
OFFICIAL LANGUAGE
The official language of the Meeting is english. no simultaneous translation is provided.
MEETING OFFICE
During the Meeting
The secretariat of the Meeting (Registration Desk, Meeting office) is located in the main lecture hall complex.
Before and After the Meeting
esDR
Rue Cingria 7
CH-1205 Geneva
switzerland
Tel: +41 22 321 48 90
fax: +41 22 321 48 92
email: office@esdr.org
Web: www.esdr.org
Information/Registration Desk
all participants must be registered. admission to scientific sessions, technical exhibition, Welcome Reception and
Gala evening is by badge only.
Opening Hours
Wednesday 9 september 12.00-17.00
Thursday 10 september 08.00-19.00
friday 11 september 08.00-18.30
saturday 12 september 08.00-15.00
38

GENERAL INFORMATION
Abstracts
all posters and oral presentations are in english. The abstract book is in the delegate bags.
Badges
a name badge is provided with your registration documents on site. for security and regulation purposes, the
wearing of this badge is compulsory at all times both inside the meeting venue and at all official events organised
within the context of the meeting.
Breaks and Lunches
Morning and afternoon coffee breaks are included in the registration fees. five coffee tickets will be given per
participant and can be used at any point during the meeting.
lunches are not included in the registration fees. The University restaurant on-site will be open. a list of other
restaurants nearby is available at the Registration Desk.
Certificates of Attendance
Certificates of attendance for pre-registered participants are issued along with the Meeting documentation upon
arrival. Participants who register on-site can request this certificate at the registration desk.
City Map
a city map is provided in the delegate bag.
Cloakroom
a cloakroom is located near the Registration Desk. Please make sure that no personal belongings are left after
closing each day. opening hours are the same as the Meeting ones.
Continuing Medical Education
acceditation statement (eaCCMe-02701-G)
The european society for Dermatological Research is accredited by the european accreditation Council for
Continuing Medical education (eaCCMe) to provide the following CMe activity for medical specialists. The
eaCCMe is an institution of the european Union of Medical specialists (UeMs):
The "39th annual esDR Meeting" is designated for a maximum of (or "for up to") 18 hours of european external
CMe credits. each medical specialist should claim only those hours of credit that he/she actually spent in the
educational activity.
eaCCMe credits are recognized by the american Medical association towards the Physician's Recognition award
(PRa). To convert eaCCMe credit to aMa PRa category 1 credit, contact the aMa.
CMe certificates can be obtained from the Registration Desk on demand.
Duplication, Recording, Photos
Photography, audio-taping, video-recording, or any other form of duplication is strictly prohibited in the session
rooms and poster areas. In the exhibition area, pictures or film are allowed only if permitted by the concerned
exhibitor. failure to comply with this rule could lead to your meeting credentials being removed.
First Aid
for assistance, please contact any of the staff members.
Insurance and Liability
The organisers will accept no liability for personal injuries sustained by or for loss or damage to property
belonging to Meeting participants, either during or as a result of the Meeting or during all tours and events.
Internet
a free wireless (wi-fi) connection is available at the meeting venue for participants with their own portable
computers. an Internet corner with fixed PCs has also been set up. Please ask the Registration Desk for more
information.
Lost and Found
lost items should be returned to the Meeting Welcome Desk. should you lose anything, please report to this desk
for assistance.
Membership
If you wish to apply for membership of the esDR, forms are available at the Registration Desk. for membership
enquiries after the meeting, please contact the esDR: office@esdr.org
Mobile Phones
Delegates are kindly requested to turn off their mobile phones when entering the meeting rooms and in the poster
areas.
39
GENERAL
INFORMATION

2009 MAP OF EXHIBITORS - GROUND FLOOR LEVEL
1
Entrance to Semmelweis
& Nekam Rooms and the
Gallery Level
CLOAKROOM
REGISTRATION
1. biotest aG
2. esDR 2010
3. TissueGnostics GmbH
4. Promocell
2 3 4 5 6
MAIN ENTRANCE
5. Cellsystems® biotechnologie Vertrieb GmbH
6. straticell
7. nature Publishing Group
8. CellnTeC advanced Cell systems, aG
7
8
Steps to Gruby & Kaposi
Rooms, Seminar Rooms
Slide Preview and Posters

POSTER INFORMATION
Installation and Removal
Please remember:
• Your poster must remain on display for the entire duration of the main ESDR Meeting (Thursday-Saturday).
• Posters must be installed on: Thursday 10 September (poster areas open at 8.00).
• Posters must be removed on Saturday 12 September between 14.00 and 15.30 at the latest.
note that posters remaining in the poster exhibition areas after 15.30 on saturday 12 september will be removed
and destroyed.
Poster Sessions
Three Poster sessions are scheduled:
• POSTER SESSION I (two x 60 minute sessions) Thursday 10 September, 19.30 to 21.30
even numbered Posters: authors stand by your posters from 19.30-20.30
odd numbered Posters: authors stand by your posters from 20.30-21.30
This session takes place during the Welcome Reception. buffet tables will be sent up close to poster areas.
• POSTER SESSION II (two x 45 minute sessions) Friday 11 September, 14.00 to 15.30
odd numbered Posters: authors stand by your posters from 14.00-14.45
even numbered Posters: authors stand by your posters from 14.45-15.30
• POSTER SESSION III (one-hour session) Saturday 12 September, 10.15-11.15
all poster presenters to be in front of posters, except those joining poster walks (see below). Coffee will be
available during this session.
authors are requested to be near their posters during these sessions in order to be able to answer any questions
and discuss their work with the participants.
Poster Prizes
several poster prizes will be awarded at the 2009 esDR Meeting. The awards will be made at a special ceremony
on friday 11 september from 16.40-16.50 in the semmelweis Room.
Poster Walks
The purpose of poster walks is to encourage interaction between junior and senior researchers and to promote
discussion on work presented at the meeting as posters.
Poster walks take place from 10.15-11.15 on saturday 12 september during Poster session III. If you wish to join
a poster walk simply meet at the meeting registration desk at this time. a list of poster walk leaders and topics
will be made known at the meeting. Confirmed walk leaders at the time of publication of this program are:
Tilo biedermann Immunology & auto-Immunity and Inflammation
antonio Costanzo Genetic Disease, Gene expression and Gene Therapy
David Kelsel Cell adhesion/Matrix biology & Growth factors and signal Transduction
luis santamaria-babi Pharma track poster walk
Richard Weller angiogenesis and Vascular biology
norbert Wikonkal Clinical Trials & Clinical Research and Therapeutics
Peter Wolf Photobiology & Pigmentation and Melanoma & Carcinogenesis
Posters that have been selected for discussion will have a sticker placed on the poster board. If your poster is
selected for a poster walk, please feel free to join the relevant walking tour group.
SLIDE PREVIEW ROOM
The slide preview room is located on the first floor.
after completing meeting registration at the Registration Desk, each speaker should go to the slide preview room.
The preview room will be open from 12.00 on Wednesday 9 september until the close of the Meeting.
all presentations must be in english. each speaker should also verify in the final program that the name of the
room and the time of the session have not changed. each meeting room is equipped with a single video-projector
(lCD for computer assisted presentations, ie, Powerpoint). speakers are reminded that they may noT connect
their own laptop to the lCD projector in the meeting rooms.
41
POSTER
INFORMATION
SLIDE
PREVIEW

ABOUT
THE ESDR
CURRENT ESDR EXECUTIVE COMMITTEE AND BOARD
Executive Committee
President
Reinhard Dummer, Zurich
President Elect (2009/2010)
eugene Healy, southampton
Immediate Past President
John McGrath, london
Secretary-Treasurer (2007-2010)
Vincent Piguet, Geneva
Assistant Secretary-Treasurer
alexander enk, Heidelberg
PAST OFFICERS OF THE ESDR BOARD
42
Board
antonio Costanzo, Rome
Robert Gniadecki, Copenhagen
sarolta Kárpáti, budapest
alain Mauviel, Paris
Philippe Musette, Rouen
Carien niessen, Cologne
nick Reynolds, newcastle
Ulpu saarialho-Kere, Helsinki
luis santamaria, barcelona
Peter steijlen, Maastrict
Peter Wolf, Graz
Year President Secretary Treasurer
1971 f. serri M. Prunieras R. Cormane
1972 o. braun-falco M. Prunieras R. Cormane
1973 s. shuster M. Prunieras R. Cormane
1974 H. Rorsman M. Prunieras R. Cormane
1975 R. Cormane C. lapière e. Christophers
1976 K. Wolff C. lapière e. Christophers
1977 e. Jung C. lapière e. Christophers
1978 e. Christophers M. Greaves T. van Joost
1979 R. Marks M. Greaves W. van Vloten
1980 H. schaefer M. Greaves W. van Vloten
1981 e. frenk M. Greaves W. van Vloten
1982 M. Greaves H. Hönigsmann W. van Vloten
1983 G. Plewig H. Hönigsmann W. van Vloten
1984 W. van Vloten H. Hönigsmann b. Vermeer
1985 a. Giannetti W.J. Cunliffe b. Vermeer
1986 J.H. saurat W.J. Cunliffe b. Vermeer
1987 P. fritsch W.J. Cunliffe b. Vermeer
1988 W.J. Cunliffe G.l. Vejlsgaard R. Willemze
1989 b. Vermeer G.l. Vejlsgaard R. Willemze
1990 J. Ring G.l. Vejlsgaard R. Willemze
1991 G.l. Vejlsgaard P.s. friedmann R. Willemze
1992 D.M. MacDonald P.s. friedmann R. Willemze
1993 G. stingl P.s. friedmann R. Willemze
1994 P.s. friedmann W. sterry P. van de Kerkhof
1995 T. Krieg W. sterry P. van de Kerkhof
Year President Secretary-Treasurer
1996 W. sterry P. van de Kerkhof
1997 K. Thestrup-Pedersen P. van de Kerkhof
1998 R. Camp P. van de Kerkhof
1999 P. van de Kerkhof l. bruckner-Tuderman
2000 I. leigh l. bruckner-Tuderman
2001 G. Zambruno l. bruckner-Tuderman
2002 l. bruckner-Tuderman l. french
2003 J. Rees l. french
2004 M. Röcken l. french
2005 l. french M. Röcken
2006 T. schwarz M. Röcken
2007 C. Pincelli M. Röcken
2008 J. McGrath V. Piguet

ESDR COMMITTEES
PHaRMa RelaTIons CoMMITTee
Philippe Musette (Chair)
Tilo biedermann
alexander enk
Robert Gniadecki
Chris Griffiths
eugene Healy
eugene o'Keefe
anthony Quinn
nick Reynolds
luis santamaria
braham shroot
MeMbeRsHIP CoMMITTee
Peter steijlen (Chair)
Carien niessen
Johann bauer
luis santamaria
PATRON MEMBERS OF THE ESDR
The esDR acknowledges the ongoing support from its Patron Members. Patron memberships help support
esDR members from eastern europe, the development of the JID and annual meeting-related projects.
Martine bagot
Paul R bergstresser
luca borradori
leena bruckner-Tuderman
anthony Chu
louis Dubertret
andrew Y finlay
lars e french
Peter s friedmann
alberto Giannetti
Giammaria Giuliani
Christopher eM Griffiths
Marcel f Jonkman
Veli-Matti Kähäri
Roland Kaufmann
Irene leigh
Monika lusky
Cornelia Mauch
ABSTRACT REVIEWERS 2009
Daniel aberdam
françois aubin
Monique aumailley
Hervé bachelez
Martine bagot
Jens-Malte baron
Johann bauer
Mark berneburg
Tilo biedermann
Markus böhm
anja bosserhoff
Jan-nico bouwes bavinck
Paul bowden
Marijke Canninga-van Dijk
andrea Cavani
Pieter-Jan Coenraads
antonio Costanzo
frank de Gruijl
Robert Dellavalle
Michael Detmar
Thomas Diepgen
beate eckes
alexander enk
Jorge frank
Marjan Garmyn
neil Gibbs
Jens Gille
Robert Gniadecki
nelleke Gruis
luisa Guerrini
Marek Haftek
Christina Has
Ulrich Hengge
bernhard Homey
Delphine Javelaud
Marcel Jonkman
Veli-Matti Kähäri
sarolta Kárpáti
Jorma Keski-oja
Reinhard Kirnbauer
Maranke Koster
Cezary Kowalewski
Peter Kurschat
Charlie lambert
bernhard lange-asschenfeldt
lionel larue
omar lupi
Thierry Magnaldo
alain Mauviel
John McGrath
James McMillan
Martin Mempel
43
sCIenTIfIC PRoGRaM CoMMITTee
eugene Healy (Chair)
Tilo biedermann
antonio Costanzo
alexander enk
Carien niessen
Vincent Piguet
nick Reynolds
Peter steijlen
easTeRn eURoPean CoMMITTee
sarolta Kárpáti (Chair)
Johann bauer (austria)
norbert Wikonkál (Hungary)
Cezary Kowalewski (Poland)
anna Zalewska (Poland)
alla Kyagova (Russia)
Michael Meurer
Colin s Munro
Dedee f Murrell
filippa nyberg
Gerd Plewig
Jonathan l Rees
Timo Reunala
lesley e Rhodes
Johannes Ring
Martin Röcken
Jean-Hilaire saurat
Thomas schwarz
Guy bruno serre
Georg stingl
erwin Tschachler
anders Vahlquist
Peter CM van de Kerkhof
The esDR acknowledges the contributions of the following 2009 esDR abstract reviewers:
Dieter Metze
laurence Michel
Maya Mockenhaupt
Maria Morasso
Colin Munro
Philippe Musette
luigi naldi
Joanna narbutt
Graham neill
Carien niessen
Teresa odorisio
Vincent Piguet
ehrhardt Proksch
nick Reynolds
Thomas Ruenger
Rudolph Rupec
Ulpu saarialho-Kere
Kerstin steinbrink
Rick sturm
Cord sunderkötter
Rolf-Markus szeimies
Des Tobin
Heiko Traupe
franz Trautinger
erwin Tschachler
Mirjana Urosevic
Peter van der Kerkhof
Maurice van steensel
Thomas Volz
stefan Weidinger
norbert Wikonkal
Hywell Williams
Pierre Wolkenstein
antony Young
Helen Young
Thomas Zollner
ABOUT
THE ESDR
ABSTRACT
REVIEWERS

AWARDS
FUTURE
ESDR MEETINGS
ESDR AWARDS AND ESDR HONORARY MEMBERSHIPS
Year ESDR Awards ESDR Honorary Members
2009 ervin epstein (Usa)
Peter friedmann (UK)
2008 Kristian Thestrup-Pedersen (Denmark)
William Cunliffe (UK)
2007 Thomas Krieg (Germany)
John stanley (Usa)
2006 Rona MacKie (UK)
Rein Willemze (netherlands)
2003 Georg stingl (austria)
Jouni Uitto (Usa)
2000 J.P. ortonne (france) M. Greaves (UK)
J-H. saurat (switzerland) e. Macher (Germany)
1999 s. Jablonska (Poland)
H. Ueki (Japan)
1998 T. nishikawa (Japan)
J. Voorhees (Usa)
1997 l. Juhlin (sweden)
1996 o. braun-falco (Germany) W. van Vloten (netherlands)
J. Thivolet (france) e. Christophers (Germany)
a. Giannetti (Italy) s. Katz (Usa)
D. McDonald (UK) s. Imamura (Japan)
Previously Awarded f. serri (Italy), M. Prunieras (france)
o. braun-falco (Germany), R. Cormane (netherlands)
R. brun (switzerland), a. Kint (belgium)
Ch. lapière (belgium), K. Mustakallio (finland)
H. Rorsman (sweden), s. shuster (UK)
K. Wolff (austria)
FUTURE ESDR MEETINGS
2010 40th Annual ESDR Meeting
Helsinki, finland
8-11 september 2010
2011 41st Annual ESDR Meeting
barcelona, spain
7-10 september 2011
2012 42nd Annual ESDR Meeting
Venice, Italy
19-22 september 2012
2013 International Investigative Dermatology (IID)
edinburgh, scotland
8-11 May 2013
44

ESDR MEMBERSHIP FORM
Application for Membership of the ESDR
For further information regarding membership of the ESDR please visit our website (www.esdr.org)
Name of applicant ___________________________________________________________________________________
Department _________________________________________________________________________________________
Institution ___________________________________________________________________________________________
Full postal address ____________________________________________________________________________________
Phone __________________________ Fax ___________________________ Email ___________________________
AREAS OF RESEARCH ACTIVITY ____________________________________________________________________________
Signature ________________________________________ Date ________________________________________________
THIS APPLICATION IS SUPPORTED BY TWO CURRENT MEMBERS OF THE ESDR
Supporter 1 Supporter 2
Name ___________________________________________ Name ____________________________________________
Email ___________________________________________ Email ____________________________________________
PLEASE INDICATE IF YOU ARE A MEMBER OF
The Society for Investigative Dermatology (SID)*
The Japanese Society for Investigative Dermatology (JSID) *
MEMBERSHIP FEES
Standard Membership EUR 115
Patron Membership EUR 230
Joint Membership for SID/JSID Members EUR 60*
Membership fee Eastern European Members EUR 60
Resident/Student Membership EUR 60
* Fully paid-up members of the SID/JSID are eligible for a reduced ESDR (Joint) Membership fee of EUR 60.
This only applies to those SID/JSID members who reside OUTSIDE Europe.
RETURN THE COMPLETED FORM TO THE ESDR OFFICE OR MEETING REGISTRATION DESK
European Society for Dermatological Research
Rue Cingria 7, 1205 Geneva, Switzerland
Telephone: +41 22 321 48 90, Fax: +41 22 321 48 92
Email: office@esdr.org
After verifying your application, you will receive an invoice for your membership fee.
45

SUPPORTED BY
http://www.euroskinresearch.org
2009 ESRF New Investigator Awards
The ESRF Scientific Committee and Board of Trustees are pleased to announce the
recipients of 2009 ESRF New Investigator Awards.
Carrie Ambler (United Kingdom)
Project Title: Epidermal Notch signalling, adult hair follicle patterning, and
inflammatory cell recruitment
Eugene de Zwart-Storm (The Netherlands)
Project Title: PPK-deafness syndromes caused by connexin26 mutations are folding
diseases
Claus Johansen (Denmark)
Project Title: Inflammation and its role in the development of non-melanoma skin
cancer
Andor Pivarcsi (Sweden)
Project Title: Investigation of the role of non-coding RNAs in non-melanoma skin
cancers
The committee and trustees thank all applicants for their submissions and congratulates
the award winners. The next round of award applications will be announced on the
Foundation’s website in the near future.
European Skin Research Foundation
7 rue Cingria, CH-1205 Geneva
Switzerland
Tel: +41 22 321 48 90 Fax: +41 22 321 48 92
office@euroskinresearch.org http://www.euroskinresearch.org

CE.R.I.E.S.
RESEARCH AWARD
The Epidermal and Sensory Research and Investigation Centre (Centre de Recherches et
Investigations Épidermiques et Sensorielles) CE.R.I.E.S. is the healthy skin research centre of
CHANEL, whose mission is to perform and encourage research of the physiology and biology
of healthy skin. In addition to conducting its own independent research, the CE.R.I.E.S. is funding
an annual award.
The CE.R.I.E.S. Research Award of 40,000 € is intended to honour a scientific researcher with a
proven track record in fundamental or clinical research work, for a one year period, on the subject of:
PHYSIOLOGY OR BIOLOGY OF HEALTHY
SKIN AND/OR ITS REACTIONS
TO ENVIRONMENTAL FACTORS
The awardee will be selected by an international jury consisting of the members of the Scientific
Advisory Board of the CE.R.I.E.S.
Previous CE.R.I.E.S. Research Award Winners:
CALL FOR APPLICATIONS
2009 Sabine Werner, Ph.D., Zurich, Switzerland:
for “Role of the cellular antioxydant glutathione in the cutaneous
UV response, in wound repair and in skin carcinogenesis”.
2008 Paul A. Khavari, M.D., Ph.D., Stanford, USA
2007 Richard L. Gallo, M.D., Ph.D., San Diego, USA
2006 Irwin Mc Lean, Ph.D., DSc, FRSE, Dundee, Scotland, UK
2005 Masayuki Amagaï, M.D., Ph.D. Tokyo, Japan
2004 Thomas Schwarz, M.D. Kiel, Germany
2003 Angela M. Christiano, Ph.D., New York, USA
2002 Dennis R. Roop, Ph.D., Houston, USA
2001 Fiona M. Watt, D. Phil., London, UK
2000 Michael Karin, Ph.D., San Diego, USA
1999 Jonathan Rees, M.D., Edinburgh, UK
1998 Jean Krutmann, M.D., Düsseldorf, Germany
1997 Jens-Michael Schröder, Ph.D., Kiel, Germany
1996 Akira Takashima, M.D., Ph.D., Texas, USA
Requests for application forms must be addressed to:
CE.R.I.E.S. Research Award
20, rue Victor Noir - 92521 NEUILLY-SUR-SEINE CEDEX - FRANCE
Tél. : 01 58 37 49 00 - Fax : 01 47 47 70 02
www.ceries.com